[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 20474
1. Liu MJ, Shin S, Li N, Shigihara T, Lee YS, Yoon JW, Jun HS: Prolonged Remission of Diabetes by Regeneration of β Cells in Diabetic Mice Treated with Recombinant Adenoviral Vector Expressing Glucagon-like Peptide-1. Mol Ther; 2007 Jan;15(1):86-93

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prolonged Remission of Diabetes by Regeneration of β Cells in Diabetic Mice Treated with Recombinant Adenoviral Vector Expressing Glucagon-like Peptide-1.
  • A single administration of rAd-GLP-1 via the tail vein into streptozotocin (STZ)-induced diabetic non-obese diabetic/severe combined immunodeficient (NOD/SCID) mice resulted in remission of diabetes within 10 days; normoglycemia remained until the experiment was terminated.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2007 The American Society of Gene Therapy. Published by Elsevier Inc. All rights reserved.
  • (PMID = 28182934.001).
  • [ISSN] 1525-0024
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


2. Lofstad GE, Reinfjell T, Hestad K, Diseth TH: Cognitive outcome in children and adolescents treated for acute lymphoblastic leukaemia with chemotherapy only. Acta Paediatr; 2009 Jan;98(1):180-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cognitive outcome in children and adolescents treated for acute lymphoblastic leukaemia with chemotherapy only.
  • OBJECTIVE: To examine cognitive outcome in children and adolescents with acute lymphoblastic leukaemia (ALL) in remission, treated with central nervous system prophylactic chemotherapy only.
  • METHOD: Thirty-five children and adolescents, age 8.4-15.3 years in long-term remission from ALL, 4.2-12.4 years post diagnosis, without relapse and no pre-diagnosis history of neurodevelopmental disorder were compared with 35 healthy controls matched for gender and age, on measures of intellectual functioning Wechsler Intelligence Scale for Children-Third Edition (WISC-III).
  • [MeSH-major] Antineoplastic Agents / adverse effects. Cognition / drug effects. Cognition Disorders / chemically induced. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ment Retard Dev Disabil Res Rev. 2006;12(3):174-83 [17061283.001]
  • [Cites] J Pediatr Psychol. 2000 Mar;25(2):59-68 [10820944.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2267-75 [11187918.001]
  • [Cites] J Pediatr Hematol Oncol. 2002 Feb;24(2):106-14 [11990695.001]
  • [Cites] Dev Neuropsychol. 2002;21(2):173-95 [12139198.001]
  • [Cites] Eur J Cancer. 2003 Feb;39(3):359-65 [12565989.001]
  • [Cites] Child Neuropsychol. 2004 Mar;10(1):14-23 [14977512.001]
  • [Cites] J Clin Exp Neuropsychol. 2004 Aug;26(5):684-97 [15370390.001]
  • [Cites] J Child Psychol Psychiatry. 1988 Nov;29(6):839-52 [3069852.001]
  • [Cites] Arch Dis Child. 1995 Aug;73(2):136-40 [7574857.001]
  • [Cites] J Clin Oncol. 1995 Oct;13(10):2490-6 [7595698.001]
  • [Cites] J Dev Behav Pediatr. 1996 Dec;17(6):392-8 [8960568.001]
  • [Cites] J Pediatr Psychol. 1997 Dec;22(6):861-70 [9494322.001]
  • [Cites] J Pediatr Psychol. 1998 Oct;23(5):333-40 [9782681.001]
  • [Cites] Arch Neurol. 1998 Dec;55(12):1561-8 [9865801.001]
  • [Cites] Cancer. 1998 Dec 15;83(12):2608-17 [9874469.001]
  • [Cites] Pediatr Blood Cancer. 2005 May;44(5):478-86 [15918215.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] Neuropsychology. 2000 Apr;14(2):189-200 [10791859.001]
  • [Cites] Cancer. 2006 Feb 15;106(4):941-9 [16411228.001]
  • (PMID = 18826490.001).
  • [ISSN] 1651-2227
  • [Journal-full-title] Acta paediatrica (Oslo, Norway : 1992)
  • [ISO-abbreviation] Acta Paediatr.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC2659382
  •  go-up   go-down


3. Li Y, Dong X, Yin Y, Su Y, Xu Q, Zhang Y, Pang X, Zhang Y, Chen W: BJ-TSA-9, a novel human tumor-specific gene, has potential as a biomarker of lung cancer. Neoplasia; 2005 Dec;7(12):1073-80
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In contrast, 28 patients with transient detection of one tumor marker or without detection of any tumor marker were all in remission.
  • Thus, BJ-TSA-9 may serve as a marker for lung cancer diagnosis and as a marker, in combination with two other tumor markers, for the prediction of the recurrence and prognosis of lung cancer patients.

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Mol Diagn. 2003 Nov;5(4):237-42 [14573783.001]
  • [Cites] Clin Cancer Res. 2005 Jan 1;11(1):173-9 [15671543.001]
  • [Cites] Cancer. 1988 Aug 15;62(4):730-4 [2840187.001]
  • [Cites] Lancet. 1991 Nov 16;338(8777):1227-9 [1719320.001]
  • [Cites] Cancer Res. 1992 Sep 1;52(17):4701-5 [1380888.001]
  • [Cites] Br J Cancer. 1995 Aug;72(2):268-76 [7640205.001]
  • [Cites] Surgery. 1996 Dec;120(6):959-64; discussion 964-5 [8957481.001]
  • [Cites] Int J Cancer. 1996 Dec 11;68(6):739-43 [8980176.001]
  • [Cites] J Clin Oncol. 1997 Jul;15(7):2701-8 [9215843.001]
  • [Cites] Lab Invest. 1997 Sep;77(3):213-20 [9314945.001]
  • [Cites] Int J Cancer. 1997 Oct 21;74(5):540-4 [9355978.001]
  • [Cites] J Clin Oncol. 1997 Nov;15(11):3388-93 [9363870.001]
  • [Cites] Chest. 1998 Jun;113(6):1526-32 [9631789.001]
  • [Cites] Cancer Res. 1998 Jul 1;58(13):2761-5 [9661888.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2632-40 [9704713.001]
  • [Cites] Diagn Mol Pathol. 1999 Dec;8(4):165-75 [10617272.001]
  • [Cites] J Pathol. 2000 Jan;190(1):6-14 [10640986.001]
  • [Cites] Br J Cancer. 2000 Jan;82(2):429-35 [10646900.001]
  • [Cites] Eur J Cancer. 2000 Apr;36(6):717-23 [10762743.001]
  • [Cites] Breast Cancer Res Treat. 2000 Mar;60(2):143-51 [10845277.001]
  • [Cites] Cancer Lett. 2000 Aug 11;156(2):141-9 [10880763.001]
  • [Cites] Oncology. 2000 Jun;59(1):81-8 [10895072.001]
  • [Cites] Semin Cancer Biol. 2000 Jun;10(3):241-9 [10936072.001]
  • [Cites] Melanoma Res. 2001 Feb;11(1):65-73 [11254117.001]
  • [Cites] Int J Cancer. 2001 Feb 15;91(4):433-7 [11251963.001]
  • [Cites] Semin Surg Oncol. 2001 Jun;20(4):278-81 [11747269.001]
  • [Cites] Br J Cancer. 2002 Jan 7;86(1):110-6 [11857021.001]
  • [Cites] Lancet Oncol. 2001 Sep;2(9):533-43 [11905707.001]
  • [Cites] Aliment Pharmacol Ther. 2002 Apr;16 Suppl 2:137-44 [11966534.001]
  • [Cites] Int J Cancer. 2002 Aug 10;100(5):592-9 [12124810.001]
  • [Cites] Br J Cancer. 1998 Nov;78(10):1368-72 [9823981.001]
  • [Cites] Melanoma Res. 1999 Aug;9(4):395-9 [10504059.001]
  • [Cites] Cancer. 1977 Oct;40(4):1621-8 [332328.001]
  • (PMID = 16354590.001).
  • [ISSN] 1522-8002
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / BPIFA1 protein, human; 0 / Biomarkers, Tumor; 0 / Glycoproteins; 0 / Neoplasm Proteins; 0 / Phosphoproteins; 0 / RNA, Messenger; 0 / Serpins; 0 / squamous cell carcinoma-related antigen
  • [Other-IDs] NLM/ PMC1501171
  •  go-up   go-down


Advertisement
4. Ziegler DS, Dalla Pozza L, Waters KD, Marshall GM: Advances in childhood leukaemia: successful clinical-trials research leads to individualised therapy. Med J Aust; 2005 Jan 17;182(2):78-81

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advances in childhood leukaemia: successful clinical-trials research leads to individualised therapy.
  • In most cases, childhood leukaemia has a fetal origin, but multiple molecular events are required after birth for pre-leukaemic cells to progress to leukaemia.
  • Cure rates for acute lymphoblastic leukaemia (ALL) now approach 80%.
  • A high level of minimal residual disease detected by polymerase chain reaction in patients with ALL in remission has profound prognostic importance and is the focus of a major Australian study attempting to prevent relapse in these children.
  • [MeSH-major] Leukemia, Myeloid / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Acute Disease. Adolescent. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Bone Marrow Transplantation / adverse effects. Child. Cranial Irradiation / adverse effects. Humans. Leukemia / diagnosis. Leukemia / physiopathology. Leukemia / therapy. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15651967.001).
  • [ISSN] 0025-729X
  • [Journal-full-title] The Medical journal of Australia
  • [ISO-abbreviation] Med. J. Aust.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 45
  •  go-up   go-down


5. Mokrzycka M, Pawlik A, Kałdońska M, Millo B: Assessment of liver function in children with acute lymphoblastic leukemia in remission. Ann Acad Med Stetin; 2006;52(3):61-5; discussion 65
Hazardous Substances Data Bank. LIDOCAINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of liver function in children with acute lymphoblastic leukemia in remission.
  • PURPOSE: Acute lymphoblastic leukemia (ALL) is the most common malignant neoplasm in children.
  • MATERIAL AND METHODS: We enrolled 17 children and young adults with ALL in remission.
  • Mean remission time was 61 +/- 30 months.
  • [MeSH-major] Liver Function Tests. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / physiopathology
  • [MeSH-minor] Adolescent. Adult. Area Under Curve. Child. Diagnosis, Differential. Female. Half-Life. Hepatitis, Chronic / complications. Hepatitis, Chronic / diagnosis. Humans. Lidocaine / analogs & derivatives. Lidocaine / pharmacokinetics. Liver / metabolism. Male. Reference Values. Remission Induction

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Liver Function Tests.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17385349.001).
  • [ISSN] 1427-440X
  • [Journal-full-title] Annales Academiae Medicae Stetinensis
  • [ISO-abbreviation] Ann Acad Med Stetin
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 7728-40-7 / monoethylglycinexylidide; 98PI200987 / Lidocaine
  •  go-up   go-down


6. Shin S, Li N, Kobayashi N, Yoon JW, Jun HS: Remission of Diabetes by β-Cell Regeneration in Diabetic Mice Treated With a Recombinant Adenovirus Expressing Betacellulin. Mol Ther; 2008 May;16(5):854-861

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Remission of Diabetes by β-Cell Regeneration in Diabetic Mice Treated With a Recombinant Adenovirus Expressing Betacellulin.
  • A single intravenous (IV) administration of rAd-BTC resulted in complete remission of streptozotocin (STZ)-induced diabetes within 2 weeks in mice.
  • Treatment of autoimmune diabetic mice with rAd-BTC in combination with an immune suppressor resulted in remission of diabetes.
  • We conclude that transient expression of BTC by rAd-BTC administration results in prolonged remission of diabetes in mice, by the regeneration of sufficient numbers of β cells in the pancreas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2008 The American Society of Gene Therapy. Published by Elsevier Inc. All rights reserved.
  • (PMID = 28178488.001).
  • [ISSN] 1525-0024
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Shammas RM, Ranganath VK, Paulus HE: Remission in rheumatoid arthritis. Curr Rheumatol Rep; 2010 Oct;12(5):355-62
MedlinePlus Health Information. consumer health - Rheumatoid Arthritis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Remission in rheumatoid arthritis.
  • With advancing therapeutic options, achieving a state of remission has become the treatment goal in rheumatoid arthritis.
  • Agreeing on what constitutes remission and what measures should be used to assess disease activity has remained a challenge.
  • Multiple remission criteria have been devised and modified, all with different strengths and limitations.
  • A consensus definition of remission will need to be achieved if we are to be able to evaluate outcomes of clinical trials and establish treatment targets for practice.
  • Remission defined as the complete absence of disease currently may not be a realistic therapeutic goal.
  • [MeSH-minor] Humans. Remission Induction. Terminology as Topic

  • Genetic Alliance. consumer health - Arthritis.
  • Genetic Alliance. consumer health - Rheumatoid arthritis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Rheumatol. 2004 Jan;31(1):1-4 [14705208.001]
  • [Cites] Rheumatology (Oxford). 2009 Sep;48(9):1092-7 [19561156.001]
  • [Cites] Arthritis Rheum. 1981 Oct;24(10):1308-15 [7306232.001]
  • [Cites] Br J Rheumatol. 1996 Nov;35(11):1101-5 [8948296.001]
  • [Cites] Nat Rev Rheumatol. 2010 Feb;6(2):68-70 [20125170.001]
  • [Cites] Autoimmun Rev. 2010 Jan;9(3):161-4 [19602456.001]
  • [Cites] Scand J Rheumatol. 2010;39(1):12-8 [20132065.001]
  • [Cites] J Rheumatol. 2010 Feb;37(2):285-90 [20080905.001]
  • [Cites] Rheumatology (Oxford). 2010 Apr;49(4):683-90 [20047979.001]
  • [Cites] Arthritis Res Ther. 2010;12(1):R3 [20055986.001]
  • [Cites] J Rheumatol. 2010 Jul;37(7):1444-53 [20516031.001]
  • [Cites] J Rheumatol. 2001 Feb;28(2):355-9 [11246676.001]
  • [Cites] Rheum Dis Clin North Am. 1997 Feb;23(1):195-212 [9031383.001]
  • [Cites] Ann Rheum Dis. 2005 Oct;64(10):1410-3 [15941836.001]
  • [Cites] Arthritis Rheum. 2005 Nov;52(11):3554-62 [16255044.001]
  • [Cites] Clin Exp Rheumatol. 2005 Sep-Oct;23(5 Suppl 39):S100-8 [16273793.001]
  • [Cites] Semin Arthritis Rheum. 2005 Dec;35(3):185-96 [16325659.001]
  • [Cites] Clin Exp Rheumatol. 2006 Nov-Dec;24(6 Suppl 43):S-1-6 [17083755.001]
  • [Cites] Clin Exp Rheumatol. 2006 Nov-Dec;24(6 Suppl 43):S-14-21 [17083757.001]
  • [Cites] Clin Exp Rheumatol. 2006 Nov-Dec;24(6 Suppl 43):S-22-8 [17083758.001]
  • [Cites] Arthritis Rheum. 2006 Dec;54(12):3761-73 [17133543.001]
  • [Cites] Z Rheumatol. 2006 May;65(3):209-12, 214-6 [16670812.001]
  • [Cites] Ann Rheum Dis. 2007 Mar;66(3):358-63 [16935911.001]
  • [Cites] Arthritis Res Ther. 2007;9(4):R72 [17662115.001]
  • [Cites] South Med J. 2008 Mar;101(3):240-5 [18364651.001]
  • [Cites] Arthritis Rheum. 2008 Aug;58(8):2241-7 [18668546.001]
  • [Cites] Arthritis Rheum. 2008 Sep;58(9):2642-51 [18759292.001]
  • [Cites] Arthritis Rheum. 2008 Sep 15;59(9):1241-8 [18759316.001]
  • [Cites] N Engl J Med. 1948 Jan 29;238(5):142-8 [18921122.001]
  • [Cites] Arthritis Rheum. 2008 Oct;58(10):2958-67 [18821687.001]
  • [Cites] Rheumatol Int. 2008 Dec;29(2):131-9 [18807254.001]
  • [Cites] BMC Musculoskelet Disord. 2009;10:41 [19389230.001]
  • [Cites] Ann Rheum Dis. 2009 Jun;68(6):914-21 [18662933.001]
  • [Cites] Arthritis Rheum. 2009 May 15;61(5):704-10 [19405006.001]
  • [Cites] J Rheumatol. 2009 May;36(5):930-3 [19332634.001]
  • [Cites] Arthritis Rheum. 2009 May;60(5):1242-9 [19404938.001]
  • [Cites] J Rheumatol. 2009 Jul;36(7):1532-5 [19487265.001]
  • [Cites] Arthritis Rheum. 2009 Aug;60(8):2262-71 [19644846.001]
  • [Cites] Arthritis Rheum. 2004 Jan;50(1):36-42 [14730597.001]
  • (PMID = 20697983.001).
  • [ISSN] 1534-6307
  • [Journal-full-title] Current rheumatology reports
  • [ISO-abbreviation] Curr Rheumatol Rep
  • [Language] eng
  • [Grant] United States / NIAMS NIH HHS / AR / K23 AR057818
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2927687
  •  go-up   go-down


8. Murphy AJ, Wells JC, Williams JE, Fewtrell MS, Davies PS, Webb DK: Body composition in children in remission from acute lymphoblastic leukemia. Am J Clin Nutr; 2006 Jan;83(1):70-4
Hazardous Substances Data Bank. DEUTERIUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Body composition in children in remission from acute lymphoblastic leukemia.
  • BACKGROUND: Changes in body composition are commonly reported in pediatric survivors of acute lymphoblastic leukemia (ALL).
  • However, the effect of ALL and of its treatment on body composition in children in remission from ALL has not been fully examined with the use of a reference method.
  • OBJECTIVES: We aimed to determine the body composition and composition of fat-free mass (FFM) in children in remission from ALL.
  • DESIGN: This cross-sectional study measured height, weight, body volume, total body water, and bone mineral content in 24 children in remission from ALL and 24 age-matched, healthy control subjects.
  • Examination of the composition of FFM made it evident that children in remission from ALL had both significantly greater hydration (P = 0.001) and lower density (P = 0.0001) of FFM than did the control children.
  • CONCLUSIONS: Children in remission from ALL may develop excess body fat.
  • [MeSH-major] Adipose Tissue / metabolism. Body Composition. Body Water / metabolism. Muscle, Skeletal / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / physiopathology
  • [MeSH-minor] Absorptiometry, Photon. Body Mass Index. Case-Control Studies. Child. Cross-Sectional Studies. Deuterium. Dexamethasone / adverse effects. Dexamethasone / therapeutic use. Female. Humans. Male. Models, Biological. Plethysmography. Prednisolone / adverse effects. Prednisolone / therapeutic use. Remission Induction

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16400052.001).
  • [ISSN] 0002-9165
  • [Journal-full-title] The American journal of clinical nutrition
  • [ISO-abbreviation] Am. J. Clin. Nutr.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 7S5I7G3JQL / Dexamethasone; 9PHQ9Y1OLM / Prednisolone; AR09D82C7G / Deuterium
  •  go-up   go-down


9. Veltroni M, Sainati L, Zecca M, Fenu S, Tridello G, Testi AM, Merlone AD, Buldini B, Leszl A, Lo Nigro L, Longoni D, Bernini G, Basso G, AIEOP-MDS Study Group: Advanced pediatric myelodysplastic syndromes: can immunophenotypic characterization of blast cells be a diagnostic and prognostic tool? Pediatr Blood Cancer; 2009 Mar;52(3):357-63
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The diagnosis of myelodysplastic syndromes (MDS) is mainly based on morphology and cytogenetic analysis.
  • PROCEDURE: We evaluated by multiparameter flow cytometry 26 MDS pediatric patients with more than 2% of blast cells at bone marrow morphological examination (17 de novo MDS and 9 secondary MDS) and 145 pediatric de novo acute myeloid leukemia (AML) cases (M3 excluded).
  • As control group, 12 healthy age-matched donors for allogenic bone marrow transplantation (BMD) and 6 regenerating bone marrow samples, collected from children with acute lymphoblastic leukemia (ALL) in remission after induction chemotherapy, were studied.
  • [MeSH-major] Blast Crisis / diagnosis. Myelodysplastic Syndromes / diagnosis
  • [MeSH-minor] Adolescent. Antigens, CD34 / analysis. Antigens, CD34 / immunology. Antigens, CD7 / analysis. Antigens, CD7 / immunology. Cell Differentiation. Child. Child, Preschool. Female. Humans. Immunophenotyping. Male. Neoplasm Staging. Precursor Cells, B-Lymphoid / cytology. Precursor Cells, B-Lymphoid / immunology. Prognosis. Survival Rate

  • Genetic Alliance. consumer health - Myelodysplastic syndromes.
  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19061215.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Antigens, CD7
  •  go-up   go-down


10. Howie AJ, Agarwal A, Sebire NJ, Trompeter RS: Glomerular tip changes in childhood minimal change nephropathy. Pediatr Nephrol; 2008 Aug;23(8):1281-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The patient was in remission at follow-up.
  • Three patients were in remission, two on no treatment at follow-up, and one on ciclosporin.
  • The other 44 children were nearly all in remission, 18 without treatment at follow-up, and the rest on various immunosuppressants, but one had persistent proteinuria and multiple segmental lesions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Bull Johns Hopkins Hosp. 1957 Apr;100(4):173-86 [13426687.001]
  • [Cites] J Pathol. 1995 Oct;177(2):191-9 [7490686.001]
  • [Cites] Nephrol Dial Transplant. 2008 Jan;23(1):186-92 [17704112.001]
  • [Cites] Nephrol Dial Transplant. 2001 Jun;16(6):1163-9 [11390715.001]
  • [Cites] J Pathol. 1986 Sep;150(1):13-20 [3783320.001]
  • [Cites] Kidney Int. 2005 Mar;67(3):987-1001 [15698437.001]
  • [Cites] Nephrol Dial Transplant. 2003 Aug;18 Suppl 6:vi33-8 [12953040.001]
  • [Cites] Pediatr Nephrol. 1993 Aug;7(4):370-4 [8398644.001]
  • [Cites] Pediatr Nephrol. 2007 Feb;22(2):215-21 [17146670.001]
  • [Cites] Kidney Int. 1991 Aug;40(2):243-50 [1942772.001]
  • [Cites] Kidney Int. 2006 Mar;69(5):920-6 [16518352.001]
  • [Cites] J Pathol. 2000 Mar;190(4):478-83 [10699998.001]
  • [Cites] Nephrol Dial Transplant. 1993;8(10):1059-63 [8272216.001]
  • [Cites] Nephrol Dial Transplant. 1993;8(7):590-9 [8396741.001]
  • [Cites] J Pathol. 1984 Mar;142(3):205-20 [6707787.001]
  • [Cites] Clin Nephrol. 1987 May;27(5):217-21 [3594937.001]
  • [Cites] Am J Kidney Dis. 2002 Jun;39(6):1168-75 [12046027.001]
  • [Cites] Kidney Int. 2004 May;65(5):1690-702 [15086908.001]
  • [Cites] J Am Soc Nephrol. 2003 Apr;14(4):908-17 [12660325.001]
  • [Cites] Am J Kidney Dis. 2004 Feb;43(2):368-82 [14750104.001]
  • (PMID = 18446377.001).
  • [ISSN] 0931-041X
  • [Journal-full-title] Pediatric nephrology (Berlin, Germany)
  • [ISO-abbreviation] Pediatr. Nephrol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 80295-33-6 / Complement C1q
  •  go-up   go-down


11. Babusikova O, Stevulova L, Fajtova M: Immunophenotyping parameters as prognostic factors in T-acute leukemia patients. Neoplasma; 2009;56(6):508-13
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunophenotyping parameters as prognostic factors in T-acute leukemia patients.
  • The main aim of this study represents the extension of our studies using multiparametric flow cytometry analysis for exact definition of membrane and intracellular (cytoplasmic and nuclear) markers of acute leukemia cells of T-phenotype.
  • The main aim was concerned to more proper T-ALL diagnosis and stage definition and identification of the prognostic factors and the useful markers for the follow-up of T-ALL in remission.
  • New knowledge of the T-cell maturation stages of hematopoietic cells in bone marrow and thymus has been applied, as each T-acute leukemia clone is representative of one blocked stage through maturation.
  • Patients with more favorable prognosis (i. e. those of cortical stage) could have been already differentiated at diagnosis from those, allocated to pro-T stage, with very immature phenotypes and of an unfavorable clinical course.
  • [MeSH-major] Antigens, CD / immunology. Antigens, Differentiation, T-Lymphocyte / immunology. Biomarkers, Tumor / immunology. HLA-DR Antigens / analysis. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19728759.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, T-Lymphocyte; 0 / Biomarkers, Tumor; 0 / HLA-DR Antigens
  •  go-up   go-down


12. Lang P, Handgretinger R: Haploidentical SCT in children: an update and future perspectives. Bone Marrow Transplant; 2008 Oct;42 Suppl 2:S54-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For patients with ALL in remission, disease-free survival at 3 years ranged between 22 and 48%.
  • [MeSH-major] Lymphocyte Depletion / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Stem Cell Transplantation. Transplantation Conditioning / methods

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18978746.001).
  • [ISSN] 1476-5365
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 57
  •  go-up   go-down


13. Ehrlich Y, Brames MJ, Beck SD, Foster RS, Einhorn LH: Long-term follow-up of chemotherapy-induced remissions in patients with disseminated nonseminomatous germ cell tumors. J Clin Oncol; 2009 May 20;27(15_suppl):5029

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 5029 Background: There is controversy concerning management of patients (pts) with nonseminomatous germ cell tumor (NSGCT) who obtain a chemotherapy-induced complete radiographic (<1cm node diameter) and serologic remission (CR).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962913.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Garbe C, Romanini A, Spitaleri G, Giovannoni L, Zardi L, Neri D, Shaw A, Menssen HD, deBraud F, Eigentler TK: Phase I/II study of the tumor-targeting human L19-IL2 monoclonal antibody-cytokine fusion protein in combination with DTIC in metastatic melanoma patients. J Clin Oncol; 2009 May 20;27(15_suppl):9064

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We observed 1 partial remission at the 15 Mio IL2 dose level after 4 treatment cycles.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962148.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Salazar LG, Slota M, Wallace D, Higgins D, Coveler AL, Dang Y, Childs J, Bates N, Waisman J, Disis ML: A phase I study of a DNA plasmid based vaccine encoding the HER2/neu (HER2) intracellular domain (ICD) in subjects with HER2+ breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):3054

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: 44 subjects with stage III and IV HER2+ breast cancer in complete remission were enrolled sequentially into 2 vaccine arms (22 subjects/arm) and received 10μg pNGVL3-hICD (Arm 1) or 100μg pNGVL3-hICD (Arm 2).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961998.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Reichardt P, Montemurro M, Gelderblom H, Blay J, Rutkowski P, Bui B, Hartmann JT, Pink D, Leyvraz S, Schütte J: Sorafenib fourth-line treatment in imatinib-, sunitinib-, and nilotinib-resistant metastatic GIST: A retrospective analysis. J Clin Oncol; 2009 May 20;27(15_suppl):10564

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients failing TKI treatment with imatinib (IM), sunitinib (SU) or nilotinib (NI) have a poor prognosis.
  • Recently, clinical activity of sorafenib in third-line treatment in patients with GIST after IM and SU failure has been shown (Wiebe et al.
  • Pts received sorafenib after failure of IM, SU and NI in fourth-line treatment.
  • All pts had failed IM, SU, NI.
  • 19 % of pts achieved partial remission and 44% disease stabilization.
  • CONCLUSIONS: This is the largest series assessing efficacy of sorafenib fourth-line treatment for IM, SU and NI refractory GIST reported yet.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963815.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. De Vita F, Orditura M, Innocente R, Vecchione L, Pinto C, Chiarion Sileni V, Martinelli E, Ruol A, Catalano G, Ciardiello F: A multicenter phase II study of induction CT with FOLFOX-4 and cetuximab followed by RT and cetuximab in locally advanced esophageal cancer (LAEC). J Clin Oncol; 2009 May 20;27(15_suppl):4546

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The pathological response rate was 68 %, with a complete histopathological remission recorded in 6 pts (27%);17 pts (53%) are still alive without residual or recurrent disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963011.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Ghielmini ME, Hsu Schmitz S, Martinelli G, Peccatori F, Hess U, Fey M, Zucca E, Stahel R, Ketterer N, Cerny T: Long-term follow-up of patients with follicular lymphoma (FL) receiving single agent rituximab at two different schedules in study SAKK 35/98. J Clin Oncol; 2009 May 20;27(15_suppl):8512

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients treated with 8 doses of rituximab over 1 year have approximately 25% and 20% chance to remain in remission at 5 and 8 years respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960877.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Jeevangi N, Joshi A, Shah M, Kannan S, Gupta S, Nair R, Khattry N: Results of autologous transplants for lymphomas from a tertiary cancer center in India. J Clin Oncol; 2009 May 20;27(15_suppl):7106

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Prognostic factors evaluated for progression free survival (PFS) were serum albumin level and body mass index (BMI) at the time of transplant, stage at diagnosis and source of stem cells, while for over all survival (OS), status of disease at transplant was also included.
  • RESULTS: The median time to transplant was 2.25 years from the time of diagnosis.
  • At the time of transplant, thirty two percent were in complete remission (CR), 50% in partial remission (PR) and 18% had refractory disease (RD).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961648.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Tarhini AA, Christensen S, Frankel P, Margolin K, Ruel C, Shipe-Spotloe J, DeMark M, Kirkwood JM: Phase II study of aflibercept (VEGF trap) in recurrent inoperable stage III or stage IV melanoma of cutaneous or ocular origin. J Clin Oncol; 2009 May 20;27(15_suppl):9028

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One patient (23<sup>rd</sup>; cutaneous, M1c) had a confirmed complete remission.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962095.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Popat UR, Saliba R, Hosing C, Khouri I, Alousi AM, Giralt SA, de Lima MJ, Qazilbash MH, Champlin R, Anderlini P: Age at diagnosis does not adversely affect outcome in patients with Hodgkin's Disease (HD) after autologous transplantation. J Clin Oncol; 2009 May 20;27(15_suppl):e19507

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Age at diagnosis does not adversely affect outcome in patients with Hodgkin's Disease (HD) after autologous transplantation.
  • : e19507 Background: Age at diagnosis is a poor prognostic factor for overall survival after standard therapy for HD.
  • We sought to evaluate the effect of older age at diagnosis on transplant outcome.
  • Seventy two patients (29%) were older than 40 years of age at the time of initial diagnosis.
  • At transplantation, 63 (25%) were in complete remission (CR); 148 (60%) were in partial remission (PR); and 37 (15%) had stable (SD) or progressive disease (PD).
  • Age at diagnosis was not a significant factor (see table ).
  • CONCLUSIONS: High-dose chemotherapy and autologous transplantation abrogate the adverse impact of age at diagnosis in patients with HD.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960864.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Mahon Fx F, Rea D, Guilhot F, Legros L, Guilhot J, Aton E, Dulucq S, Reiffers J, Rousselot P: Persistence of complete molecular remission in chronic myeloid leukemia after imatinib discontinuation: Interim analysis of the STIM trial. J Clin Oncol; 2009 May 20;27(15_suppl):7084

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Persistence of complete molecular remission in chronic myeloid leukemia after imatinib discontinuation: Interim analysis of the STIM trial.
  • : 7084 Background: Imatinib (IM) has greatly improved survival in chronic myeloid leukemia (CML).
  • However, IM must be continued for an indefinite period of time.
  • A multicenter trial "Stop Imatinib" (STIM) was initiated in July 2007, in order to evaluate the persistence of complete molecular remission (CMR) after stopping IM and determine factors associated with CMR persistence.
  • METHODS: Inclusion criteria were IM treatment duration ≥3 years and sustained CMR, defined as BCR-ABL transcripts below a detection threshold of a 5-log reduction (undetectable by RQ-PCR) for ≥2 years.
  • In case of relapse, pts were rechallenged with IM at 400 mg daily.
  • Median age was 62 (29-80), 31 pts had been treated with IFN prior to IM and 29 with IM frontline (de novo).
  • Relapse occurred in 37 pts within 6 months of IM discontinuation.
  • All patients in molecular relapse were sensitive to IM reintroduction.
  • No differences in terms of demography, duration of IM treatment and CMR duration were found between pts who relapsed and those who did not.
  • At M9, the probability of persistent CMR was 46% (95% CI: 32-59%), 53% (95% CI: 33-69%) for previously IFN-treated pts and 39% (95% CI: 20-58%) for de novo pts (p = 0.54).
  • CONCLUSIONS: Our data confirm that CMR can be long-lasting after discontinuation of IM.
  • Using stringent criteria, it is possible to stop IM in patients with sustained CMR, even in those treated with IM as a single agent.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961477.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Mukhopadhyay A, Gupta P, Mukhopadhyay S, Dey S, Basak J, Pandey R: Result of adolescent acute lymphoblastic leukemia protocol (MCP 841) from a developing country. J Clin Oncol; 2009 May 20;27(15_suppl):10046

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Result of adolescent acute lymphoblastic leukemia protocol (MCP 841) from a developing country.
  • : 10046 Background: Acute Lymphatic Leukemia is a curable disease in the range of 80 - 90% in developed countries by aggressive protocol like BFM, St. Judes' but result is much less in adolescence age group (60-70%).
  • RESULTS: Remission induction was seen in 65 (86.7%) of the patients.
  • CONCLUSIONS: The data of acute lymphatic leukemia in adolescent is not satisfactory as compared to other pediatric patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962472.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Terada KY, Davis J, Kitayama J, Shimizu D: Hormonal treatment of metastatic endometrial stromal sarcoma. J Clin Oncol; 2009 May 20;27(15_suppl):e16576

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Treatment with progestins or aromatase inhibitors may result in remission or stable disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961495.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Pourtsidis AG, Doganis D, Baka M, Bouhoutsou D, Varvoutsi M, Servitzoglou M, Kosmidis S, Synodinou M, Strantzia C, Kosmidis H: Successful treatment with minimal chemotherapy followed by low-dose involved field radiotherapy in children with Hodgkin's disease: A 20-year experience in a single institution in Greece. J Clin Oncol; 2009 May 20;27(15_suppl):10052

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among 35 boys and 23 girls, age at diagnosis 4.5 - 15 years (median 12), all aged 7 years or less were boys (8/58).
  • RESULTS: Complete remission (CR) was achieved in all patients.
  • Fifty-three pts (DFS: 91.4%) live in their first complete remission.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962448.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Gisselbrecht C, Glass B, Mounier N, Gill D, Linch D, Trneny M, Bosly A, Shpilberg O, Ketterer N, Moskowitz C, Schmitz N: R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by autologous stem cell transplantation: CORAL study. J Clin Oncol; 2009 May 20;27(15_suppl):8509

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The overall response rate was 63%, with 38% complete remission.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960863.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Ghavamzadeh A, Alimoghaddam K, Karimi A, Manookian A, Asadi M, Maheri R, Shamshiri A: Outpatient stem cell transplantation for multiple myeloma. J Clin Oncol; 2009 May 20;27(15_suppl):e19553

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: 142 patients with multiple myeloma (MM) in complete remission (CR) or partial remission (PR) received ASCT on an outpatient or inpatient basis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961089.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Erba HP, Kantarjian HM, Claxton DF, Arellano M, Lyons RM, Kovacsovics TJ, Gabrilove J, Eckert S, Faderl S: Updated remission duration and survival results of single-agent clofarabine in previously untreated older adult patients with acute myelogenous leukemia (AML) unlikely to benefit from standard induction chemotherapy due to unfavorable baseline risk factor(s). J Clin Oncol; 2009 May 20;27(15_suppl):7062

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Updated remission duration and survival results of single-agent clofarabine in previously untreated older adult patients with acute myelogenous leukemia (AML) unlikely to benefit from standard induction chemotherapy due to unfavorable baseline risk factor(s).
  • : 7062 Background: The CLASSIC II trial has previously reported an independently confirmed overall remission rate of 46% (38% CR and 8% CRp) and 30- and 60-day mortality rates of 9.8% and 16.1%, respectively (Blood 112: 558, 2008).
  • We now report updated duration of remission (DOR), disease-free survival (DFS), and overall survival (OS).
  • METHODS: Single arm, multi-center, phase II, open-label, 2-stage study of patients with untreated AML, ≥60 years old, and at least one adverse prognostic factor: age ≥70 years, antecedent hematologic disorder (AHD), PS = 2, and/or intermediate/unfavorable risk karyotype.
  • Patients were followed for at least 6 months past remission (CR/CRp).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961436.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Handkiewicz-Junak D, Roskosz J, Kropinska A, Kozielski J, Krzywiecki A, Krajewska J, Krajewska J, Puch Z, Olczyk T, Jarzab B: Efficacy and safety of radioiodine in the treatment of disseminated differentiated thyroid cancer (DTC) in children. J Clin Oncol; 2009 May 20;27(15_suppl):10065

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Complete scintigraphic and radiological remission was achieved in 38 (86%) children.
  • CONCLUSIONS: Complete remission of distant metastases can be achieved in about 85% of children with DTC treated with radioiodine.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962500.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Cocorocchio E, Vanazzi A, Botteri E, Alietti A, Negri M, Bassi S, Preda L, Travaini L, Peccatori FA: Prognostic role of interim &lt;sup&gt;18&lt;/sup&gt;FDG-PET in Hodgkin lymphoma: A single-center experience. J Clin Oncol; 2009 May 20;27(15_suppl):e19520

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report our experience with the intent of evaluate prognostic role of <sup>18</sup>FDG-PET in terms of long term complete remission (CR).
  • All patients underwent <sup>18</sup>FDG-PET scans at diagnosis, after the fourth cycle in the VBM group, after the third cycle in the ChlVPP/ABVVP (interim <sup>18</sup>FDG-PET), at the end of treatment in all patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960937.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Armstrong GT, Pan Z, Ness K, Srivastava D, Robison LL: Temporal trends in cause-specific late mortality among five-year survivors of childhood cancer. J Clin Oncol; 2009 May 20;27(15_suppl):10004

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONCLUSIONS: All-cause late mortality has improved with more recent eras, attributable to reduced rates of mortality from progression of primary disease (i.e., durable remission).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962548.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Medeiros BC, Gotlib JR, Coutre SE, Jones C, Khan SA, Rajwanshi R, Rajwanshi R, Zehnder J, Zehnder J: Interim results of protracted low doses of temozolomide in high-risk acute myeloid leukemia. J Clin Oncol; 2009 May 20;27(15_suppl):7052

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interim results of protracted low doses of temozolomide in high-risk acute myeloid leukemia.
  • : 7052 Background: High treatment-related mortality and low response rates often discourage elderly patients with acute myeloid leukemia from receiving treatment.
  • De novo AML was diagnosed in eight patients and five patients had s-AML.
  • Six patients (6/13) achieved a complete remission (CR) after 1 cycle of therapy (1/2 for patients with methylated and 5/11 for patients with unmethylated AGAT promoter).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961417.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Faderl S, Thomas DA, Gandhi V, Huang X, Borthakur G, O'Brien S, Ravandi F, Plunkett W, Bretz JL, Kantarjian HM: Results of a phase I study of clofarabine (CLO) plus cyclophosphamide (CY) in adult patients (pts) with relapsed and/or refractory acute lymphoblastic leukemia (ALL). J Clin Oncol; 2009 May 20;27(15_suppl):7020

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of a phase I study of clofarabine (CLO) plus cyclophosphamide (CY) in adult patients (pts) with relapsed and/or refractory acute lymphoblastic leukemia (ALL).
  • Twenty-one pts had pre-B ALL, 5 pts pre-T/T ALL, 1 pt mature B ALL, and 3 pts biphenotypic acute leukemias.
  • Among the remainder, preceding median remission duration was 8.6 mos (1-39 mos).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961382.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Guida M, Porcelli G, Ruggieri E, Zito A, Mattioli V, Montemurro S, Colucci G: Electrochemoterapy (ECT) for the treatment of superficial tumor localizations. J Clin Oncol; 2009 May 20;27(15_suppl):e13526

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • About 50% of lesions remained in remission for a long period (median 8 months, range 1-23+); 11 of 12 pts previously undergone surgical debulking never relapsed in the treated area.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961294.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Hauke RJ, Enke C: Phase I study of extended field intensity modulated radiation therapy (EF-IMRT) and docetaxel in patients with node-positive prostate cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e16154

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Seven of 9 patients are now beyond the 2 year post-radiation period; 4 patients remain in remission; one patient developed primary lung cancer; another was lost to follow up at 1 year post-radiation and 3 had relapsed disease within the 2 year post-radiation window.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963414.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Kim C, Lee CW, Klasa R, Shah A, Savage KJ: Long-term survival of patients with metastatic melanoma (MM) treated with dacarbazine (DTIC) or temozolomide (TMZ). J Clin Oncol; 2009 May 20;27(15_suppl):9054

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Eleven patients survived > 5 years (range 5-27.5), and 6 patients remain in remission (5 CR, 1 PR).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962130.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Bonini A, Tieghi A, Gamberi B, Imovilli A, Carbonelli C, Spaggiari L, Gugliotta L: Caspofungin for invasive aspergillosis: A single-centre prospective study. J Clin Oncol; 2009 May 20;27(15_suppl):e20618

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The diagnoses were: leukemia 44, myeloma 3, lymphoma 16; the disease's phases were: new onset 24, remission 16, relapse 23.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961616.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Lipshultz SE, Scully RE, Lipsitz SR, Sallan SE, Silverman LB, Miller TL, Orav EJ, Colan SD: Gender differences in long-term dexrazoxane cardioprotection in doxorubicin-treated children with acute lymphoblastic leukemia. J Clin Oncol; 2009 May 20;27(15_suppl):10005

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gender differences in long-term dexrazoxane cardioprotection in doxorubicin-treated children with acute lymphoblastic leukemia.
  • Adding dexrazoxane (DZR) to DOX treatment resulted in reduced myocardial injury in children with acute lymphoblastic leukemia (ALL) during Dana-Farber Cancer Institute Protocol 95-01.
  • METHODS: We centrally remeasured echocardiograms from childhood high-risk ALL survivors in their first continuous remission who were randomly assigned to treatment with DOX only (n = 66; 30 mg/m<sup>2</sup>/dose for 10 doses) or DOX plus DZR 30 minutes prior (n = 68; 300 mg/m<sup>2</sup>/dose).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962530.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Kolarevic D, Tomasevic Z, Andjelic Dekic N, Milosevic S, Jelic S: The differences in rate and duration of complete remission between HER2-positive and HER2-negative inflammatory breast carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):1106

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The differences in rate and duration of complete remission between HER2-positive and HER2-negative inflammatory breast carcinoma.
  • According to literature, complete remission (CR) can be achived in more than 50% of patients with combinatination of chemotherapy and trastuzumab.
  • Median age at diagnosis was 59 (ranges 35-81).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962166.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Ghavamzadeh A, Allahyari A, Alimoghaddam K, Karimi A, Shamshiri A, Abolhasani R, Manookian A, Asadi M, Khatami F: Outpatient versus inpatient autologous stem cell transplantation for malignant hematologic disorders. J Clin Oncol; 2009 May 20;27(15_suppl):7042

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 7042 Background: High-dose chemotherapy with autologous stem cell support is utilized for the treatment of a variety of malignancies including Hodgkin/non-Hodgkins lymphoma and acute leukemias.
  • Also all the patients were in complete remission and without significant organ failure.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961405.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Biswajit D, Rejiv R, Manjunath N, Prasad G, Lakshmi S, Devika P, Geetha K, Sagar TG: Imatinib mesylate experience of young patients with chronic myeloid leukemia in chronic phase-Care to cure. J Clin Oncol; 2009 May 20;27(15_suppl):7072

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imatinib mesylate experience of young patients with chronic myeloid leukemia in chronic phase-Care to cure.
  • : 7072 Background: Chronic myeloid leukemia (CML) with introduction of imatinib has been transformed into a chronic illness.
  • Complete hematological remission (CHR) was seen in 96.7%.Cytogenetic (FISH) and molecular (RTPCR) monitoring was possible in 53.2% and 17.3%, respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961455.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Ozyar E, Gultekin M, Alp A, Hascelik G, Ugur O, Atahan IL: Use of plasma Epstein-Barr virus DNA monitoring as a tumor marker in follow-up of patients with nasopharyngeal carcinoma: preliminary results and report of two cases. Int J Biol Markers; 2007 Jul - Sep;22(3):194-199

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A prospective study was initiated to investigate this correlation in 125 patients (34 pretreatment [Group A], 78 in remission [Group B] and 13 relapsed [Group C]) and 19 healthy controls.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28207133.001).
  • [ISSN] 1724-6008
  • [Journal-full-title] The International journal of biological markers
  • [ISO-abbreviation] Int. J. Biol. Markers
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


43. Milani C, Castillo J: HIV-associated peripheral T-cell lymphoma. J Clin Oncol; 2009 May 20;27(15_suppl):e19551

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Therapy for PTCL was administered in 23 cases (68%), while 10 cases (30%) did not receive therapy; 9 of the treated patients (39%) received CHOP with a 33% remission rate.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961094.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. O'Brien MM, Donaldson SS, Whittemore AS, Link MP: Second malignant neoplasms among survivors of pediatric Hodgkin disease treated with low-dose radiation (15-25.5 Gy) and chemotherapy. J Clin Oncol; 2009 May 20;27(15_suppl):10003

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: One hundred ten of 112 patients achieved remission; median follow-up is 20.6 years.
  • Four patients developed secondary leukemia.
  • Cumulative incidence of any SMN is 17% (95%CI 10.5-26.7) at 20 years following HD diagnosis.
  • In univariate analysis, older age at HD diagnosis (>11 years) and female gender were associated with SMN (p<0.05).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962547.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Zamagni C, De Iaco P, Rosati M, Cacciari N, Rosati F, Rubino D, Martoni AA: Effect of six courses of neoadjuvant chemotherapy on pathological complete remission in advanced ovarian cancer. J Clin Oncol; 2009 May 20;27(15_suppl):5513

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of six courses of neoadjuvant chemotherapy on pathological complete remission in advanced ovarian cancer.
  • We conducted this study to verify the incidence of optimal pathological remission after 6 courses of NACT.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962463.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Ferreri AJ, Reni M, Martelli M, Pangalis G, Frezzato M, Cabras G, Fabbri A, Corazzelli G, Zucca E, Cavalli F: Randomized phase II trial on primary chemotherapy with high-dose methotrexate (HD-MTX) alone or associated with high-dose cytarabine (HD-araC) for patients with primary CNS lymphoma (I.E.L.S.G. #20 Trial): Tolerability, activity, and survival analyses. J Clin Oncol; 2009 May 20;27(15_suppl):8545

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pts were stratified based on IELSG score and centre irradiation policy for pts >60 ys in complete remission (CR) after cht.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960962.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Naik SG, Negrin R, Laport G, Miklos D, Shizuru J, Arai S, Blume K, Wong R, Lowsky R, Johnston L: Long-term outcomes of high-dose therapy using busulfan, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for patients with high-risk or advanced stages of myeloid malignancies. J Clin Oncol; 2009 May 20;27(15_suppl):7033

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Disease status at transplantation was induction failure (IF) acute myeloid leukemia (AML) (n = 10), HR AML in 1st complete remission (CR1) n = 11, in CR2 (n = 5), in CR3 (n = 2), relapsed refractory (RR) AML (n = 14), chronic myeloid leukemia (CML) in second chronic phase (n = 6), blast crisis (n = 2), myelofibrosis (n = 6), myeloproliferative disorders (n = 2), and MDS (n = 38).
  • Cumulative incidence of acute (grade 3-4) and chronic GVHD was 28% (95% CI 19%-37%) and 38% (95% CI 24%-52%), respectively.
  • Relapse and acute GVHD remain significant causes of mortality.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961395.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Smaili F, Bounedjar A, Ferhat R, Bouzid K: Results at 5 years of intra vesical gemcitabine (G) single agent as adjuvant chemotheray in superficial transitional cell carcinoma (TCC) of the bladder. J Clin Oncol; 2009 May 20;27(15_suppl):e16087

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: At a median follow-up time 60 months, all patients were evaluable for tumor response: 23(38, 3%) patient had a persistant complete remission after treatment, 26 patients (43,3%) had a superficial relapse of TCC, six patients (10%) had progressive disease: four with muscle invasion and two with distant metastasis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963109.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Vigil CE, Ayala E, Sokol L: Autologous stem cell transplant in peripheral T cell lymphomas: Single institution 10-year retrospective analysis. J Clin Oncol; 2009 May 20;27(15_suppl):e19538

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e19538 Background: Peripheral T-cell lymphoma is a rare entitydisease, compromising 10% of non-Hodgkin's lymphoma worldwide and 5% of all lymphoid neoplasms in the United States.
  • METHODS: A retrospective analysis on patients with diagnosis of peripheral T-cell lymphoma receiving autologous stem cell transplant was conducted (January 1997 to July 2008).
  • Seventeen patients (58.62%) presented with an aa IPI score greater than 2.4 patients were in complete remission, 15 at first relapse, 4 in greater than 1 episode, and 6 with refractory disease at the time of transplantion.Kaplan Meier overall survival (OS) 72 and relapse free survival (RFS) was 62 at 1 year respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961010.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Lonetti A, Iacobucci I, Ferrari A, Messina M, Cilloni D, Soverini S, Papayannidis C, Baccarani M, Foà R, Martinelli G: Expression of different isoforms of the B-cell mutator activation-induced cytidine deaminase (AID) in BCR-ABL1-positive acute lymphoblastic leukemia (ALL) patients. J Clin Oncol; 2009 May 20;27(15_suppl):7049

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of different isoforms of the B-cell mutator activation-induced cytidine deaminase (AID) in BCR-ABL1-positive acute lymphoblastic leukemia (ALL) patients.
  • : 7049 Since the activation-induced cytidine deaminase (AID) enzyme can target non-immunoglobulin (Ig) genes and may even act as a genome-wide mutator, we investigated AID expression in BCR-ABL1-positive ALL and in chronic myeloid leukemia (CML) at the time of progression to blast crisis.
  • On the 61 de novo adult BCR-ABL1-positive ALL patients (pts), AID mRNA and protein were detected in 36 (59%); their expression correlated with BCR-ABL1 transcript levels and disappeared after treatment with tyrosine kinase inhibitors at the time of remission.
  • AID expression was also found in lymphoid blast crisis CML (50%), but not in myeloid lineage or in chronic phase CML.
  • Our findings show that BCR-ABL1-positive ALL cells aberrantly express different isoforms of AID that can act as mutator outside the Ig gene loci in promoting genetic instability in leukemia cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961429.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Ferron G, Aziza R, Delannes M, Filleron T, Marquès B, Labarre D, Labarre D, Chevreau C: Detection of local recurrences of limb soft-tissue sarcomas: Is magnetic resonance imaging (MRI) relevant? J Clin Oncol; 2009 May 20;27(15_suppl):10582

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Forty-one patients (33%) prematurely withdrew from the planned radiological surveillance due to metastasis diagnosis (15 cases), 5-year remission duration (5 cases), other reasons (12 cases), and drop out (9 cases).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963876.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Harrington K, Hingorani M, Tanay M, Matthews J, Newbold K, Renouf L, Coffin RS, McNeish I, Nutting C: Phase I/II dose escalation study of OncoVex&lt;sup&gt;GM-CSF&lt;/sup&gt; and chemoradiotherapy (CRT) in untreated stage III/IV squamous cell cancer of the head and neck (SCCHN). J Clin Oncol; 2009 May 20;27(15_suppl):6018

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 11 of 17 (65%) pts remain in remission at median follow-up of 23 months.
  • Long-term locoregional control was achieved in 100% of pts, 65% of pts remaining in complete remission.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962425.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Fischer JR, Griesinger F, Fink T, Buchholz E, Salm T, Marseille A, Wolf M: Docetaxel-carboplatin chemotherapy in combination with cetuximab in patients with locally advanced or metastasized non-small cell lung cancer (NSCLC): Interim results of the nonrandomized phase II study TaxErb. J Clin Oncol; 2009 May 20;27(15_suppl):e19062

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The primary endpoint was response rate defined as complete or partial remission according to RECIST.
  • 0 pts had complete and 11 pts had partial remission resulting in a response rate of 40.7% (95%CI: 22%-59%) based on intention to treat.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962134.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Granberg C, Thompson RH, Quevedo JF, Karnes RJ, Frank I, Kwon ED, Blute ML: Down-staging of locally advanced prostate cancer with anti-CTLA-4 monoclonal antibody prior to radical prostatectomy. J Clin Oncol; 2009 May 20;27(15_suppl):e16103

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • On final pathology, both exhibited extensive treatment effect, remission of SV involvement, and robust disaggregation of solid tumors resulting in only microscopic, non-contiguous foci of residual intraprostatic cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963333.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Kawaguchi K: Robotic radiosurgery for severe recurrent and primary head and neck cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e17038

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For the primary cases, significant tumor reduction were noted at the third-month follow-up, all the 14 patients went into remission with 5 cases in CR, and 9 cases in PR.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961782.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Marinaccio M, De Marino E, Mele E, Catacchio R, Pellegrino C, Pinto V, Schonauer S: Paclitaxel, ifosfamide, and cisplatin regimen as neoadjuvant chemotherapy in young women with locally advanced squamous cervical cancer. J Clin Oncol; 2009 May 20;27(15_suppl):5587

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Eligibility included proven histologically diagnosis of squamous cervical carcinoma, FIGO stage IB2/IIA>4cm/IIB, measurable disease, ECOG PS 0-2, no prior therapy and age under 49 years.
  • CONCLUSIONS: Our results indicate that TIP regimen-based NAC is an attractive option in young women with squamous LACC (IB2,IIA >4cm, IIB) that strongly desire surgery.The rate of patients with a prolonged remission of disease (82.0%) suggests that the clinical benefit of TIP regimen-based NAC followed by surgery may be comparable to chemoradiotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962390.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Maris MB, Ravandi F, Stuart R, Stone R, Cripe L, Cooper M, Strickland S, Turturro F, Stock W, Berman C: A phase II study of voreloxin as single agent therapy for elderly patients (pts) with newly diagnosed acute myeloid leukemia (AML). J Clin Oncol; 2009 May 20;27(15_suppl):7048

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of voreloxin as single agent therapy for elderly patients (pts) with newly diagnosed acute myeloid leukemia (AML).
  • Eligibility: newly diagnosed AML (de novo or secondary AML), pts age ≥ 60 and ≥ 1 additional adverse risk factor (age ≥ 70, secondary AML, intermediate or unfavorable cytogenetics, or PS 2).
  • Median duration of remission has not been reached.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961427.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Diehl V, Haverkamp H, Mueller R, Mueller-Hermelink H, Cerny T, Markova J, Ho AD, Kanz L, Greil R, Engert A: Eight cycles of BEACOPP escalated compared with 4 cycles of BEACOPP escalated followed by 4 cycles of BEACOPP baseline with or without radiotherapy in patients in advanced stage Hodgkin lymphoma (HL): Final analysis of the HD12 trial of the German Hodgkin Study Group (GHSG). J Clin Oncol; 2009 May 20;27(15_suppl):8544

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Treatment outcome: complete remission 92.4%; early progression 2.2%; progression/relapse 7.8% (6.6% and 8.5%).
  • A total of 156 (9.9%) deaths (72 vs 84) have been observed (22 vs 32 acute or salvage treatment toxicity; 15 vs 24 HL; 22 vs 13 secondary neoplasia).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960959.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Partap S, Murphy PA, Vogel H, Barnes PD, Edwards MS, Fisher PG: Efficacy and tolerability of intrathecal liposomal cytarabine for central nervous system embryonal tumors. J Clin Oncol; 2009 May 20;27(15_suppl):2064

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: A cohort of 17 patients were treated with liposomal cytarabine at diagnosis of CNS embryonal tumor (2 PNET, 3 ATRT) or relapse (12 MB [7 average-risk, 5 high-risk]); nine had leptomeningeal metastases.
  • Seven patients remain alive (4 initial and 3 relapse) with five in continuous complete remission (2 ATRT) for a median 13.7 months from first liposomal cytarabine.
  • One-third of our cohort remains in remission from otherwise fatal diagnoses.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964690.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Hafeez M, Shaharyar A, Zia N, Rasheed H: A phase II feasibility study of cytarabine and idarubicin combination in relapsed or refractory adult acute lymphoblastic leukemia. J Clin Oncol; 2009 May 20;27(15_suppl):e18002

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II feasibility study of cytarabine and idarubicin combination in relapsed or refractory adult acute lymphoblastic leukemia.
  • It was empirically decided that the study will only be considered feasible if more then ten patients achieve a complete remission.
  • Eleven patients achieved complete remission.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964000.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Rubnitz J, Inaba H, Ribeiro R, Pounds S, Pui C, Leung W: Pilot study of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol; 2009 May 20;27(15_suppl):10034

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pilot study of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia.
  • We hypothesized that the transplantation of purified haploidentical NK cells may be a safe and effective form of consolidation therapy that will reduce the risk of relapse among children with acute myeloid leukemia (AML) who are not treated with HSCT.
  • In this pilot study, we assessed the safety, feasibility, and engraftment of NK cell infusions in 10 patients with AML in first remission.
  • RESULTS: The 10 patients had a median age of 2.5 years (range, 8 months to 21 years) and a median leukocyte count of 62 x 10<sup>9</sup>/L (range, 4 to 487) at diagnosis.
  • With a median follow-up time of 637 days, all patients remain in remission.
  • CONCLUSIONS: Haploidentical NK cells can be safely administered to AML patients who are in remission.
  • We have recently opened a new trial to evaluate the efficacy of NK cell therapy in children in first remission of AML.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962581.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. Aigner N, Petje G, Schneider W, Meizer R, Wlk M, Kotsaris S, Knahr K, Landsiedl F: Bone marrow edema syndrome of the femoral head : Treatment with the prostacyclin analogue iloprost vs. core decompression: An MRI-controlled study. Wien Klin Wochenschr; 2005 Feb;117(4):130-135

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Knochenmarködemsyndrom des Hüftkopfes : Behandlung mit dem Prostazyklinanalogon Iloprost im Vergleich zur Hüftkopfbohrung: Eine MRT-kontrollierte Studie.
  • MRI controls showed complete remission in all hips.
  • MRI controls showed complete remission of BMES in 14 hips, residual focal bone marrow edema in four hips and a small osteonecrotic area in two hips.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28108806.001).
  • [ISSN] 1613-7671
  • [Journal-full-title] Wiener klinische Wochenschrift
  • [ISO-abbreviation] Wien. Klin. Wochenschr.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Austria
  • [Keywords] NOTNLM ; Avascular necrosis / Bone marrow edema syndrome / Core decompression / Iloprost / Vasoactive drug
  •  go-up   go-down


63. Altavilla G, Arrigo C, Marabello G, Galletti G, Santarpia M, Sauta M, Pitini V: Amplification and overexpression of the PSMB5 gene contributes to bortezomib resistance in retreatment of patients with multiple myeloma. J Clin Oncol; 2009 May 20;27(15_suppl):e19500

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Between January and June 2008 pts with secretory MM on relapse were elegible for bortezomib re-treatment (1.3 or 1.0 mg/mq on days 1,4,8 and 11 of a 21 day cycle) if they had at least a partial remission to a bortezomib based on most recent treatment and a free interval of at least 6 months since the last dose.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960887.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Ridolfi L, Fiammenghi L, Petrini M, Granato AM, Ancarani V, Pancisi E, Valmorri L, Riccobon A, Ridolfi R: Dendritic cell vaccination in melanoma patients: Update and subgroup analysis of clinical response to post-vaccine treatment. J Clin Oncol; 2009 May 20;27(15_suppl):9042

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the literature, higher response rates than those normally obtained have been reported after second-line chemotherapy in patients with non small cell lung cancer pre-treated with vaccines and in patients with follicular B-cell lymphoma vaccinated with an anti-idiotype vaccine whilst in remission.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962107.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Pemmaraju N, Kantarjian H, Ravandi F, O'Brien S, Wierda W, Thomas D, Garcia-Manero G, Borthakur G, Pierce S, Cortes J: Acute myeloid leukemia (AML) in adolescents and young adults (AYA): The M. D. Anderson Cancer Center (MDACC) experience. J Clin Oncol; 2009 May 20;27(15_suppl):7051

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute myeloid leukemia (AML) in adolescents and young adults (AYA): The M. D. Anderson Cancer Center (MDACC) experience.
  • This cohort included 27 (17%) pts with Core Binding Factor (CBF)-AML [inv(16), t(8:21)] and 19 pts (12%) with acute promyelocytic leukemia (APL).
  • Complete remission (CR) rates were 89% for CBF AML, 79% for APL, and 75% for all other pts.
  • Outcome is better for pts with CBF leukemia (3 yr survival 56%, sustained CR 49%) and APL (3 yr survival 51%, sustained CR 36%) compared to other AML (3 yr survival 28%, sustained CR 24%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961415.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Nickenig C, Buecklein V, Lindner LH, Abdel-Rahman S, Kuhlencordt M, Hiddemann W, Issels RD: Ifosfamide, carboplatin, and etoposide (ICE) in combination with regional hyperthermia (RHT) in chemotherapy-pretreated nonresponders with locally advanced high-risk soft tissue sarcoma (HR-STS). J Clin Oncol; 2009 May 20;27(15_suppl):10581

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In 35 of 49 pts evaluable for OR, 26% achieved objective remission (1 CR + 8 PR), 51% showed stable disease (18 SD) and 23% progressive disease (8 PD).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963873.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Cho BS, Lee S, Kim YJ, Chung NG, Eom KS, Kim HJ, Min CK, Cho SG, Kim DW, Lee JW, Min WS, Kim CC: Reduced-intensity conditioning allogeneic stem cell transplantation is a potential therapeutic approach for adults with high-risk acute lymphoblastic leukemia in remission: results of a prospective phase 2 study. Leukemia; 2009 Oct;23(10):1763-70
Hazardous Substances Data Bank. VIDARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduced-intensity conditioning allogeneic stem cell transplantation is a potential therapeutic approach for adults with high-risk acute lymphoblastic leukemia in remission: results of a prospective phase 2 study.
  • The aim of this prospective study was to investigate the feasibility of reduced-intensity conditioning (RIC) allogeneic stem cell transplantation (SCT) in 37 adults with high-risk acute lymphoblastic leukemia (ALL) in first (n=30) or second (n=7) complete remission (CR).
  • The cumulative incidence of acute (grades II-IV) and chronic GVHD was 43.2 and 65.6%, respectively.
  • This study suggests that RIC-SCT is a potential therapeutic approach for adults with high-risk ALL in remission who are ineligible for myeloablative transplantation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Transplantation Conditioning
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Feasibility Studies. Female. Graft Survival. Graft vs Host Disease / etiology. Graft vs Host Disease / mortality. Graft vs Host Disease / prevention & control. Humans. Male. Melphalan / administration & dosage. Middle Aged. Prospective Studies. Remission Induction. Risk Factors. Survival Rate. Transplantation, Homologous. Treatment Outcome. Vidarabine / administration & dosage. Vidarabine / analogs & derivatives. Young Adult

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19440217.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine; Q41OR9510P / Melphalan
  •  go-up   go-down


68. Ghobrial IM, Matous J, Padmanabhan S, Badros A, Chuma S, Leduc R, Rourke M, Kunsman J, Harris B, Warren D, Richardson P: Phase II trial of combination of bortezomib and rituximab in relapsed and/or refractory Waldenstrom macroglobulinemia. J Clin Oncol; 2009 May 20;27(15_suppl):8535

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Complete remission and near complete remission occurred in 2 (6%), partial remission in 17 (48%), and minimal response in 10 (29%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960930.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Abdelrazik N, Fouda M: Once weekly recombinant human erythropoietin treatment for cancer-induced anemia in children with acute lymphoblastic leukemia receiving maintenance chemotherapy: a randomized case-controlled study. Hematology; 2007 Dec;12(6):533-41
Hazardous Substances Data Bank. EPOETIN ALFA .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Once weekly recombinant human erythropoietin treatment for cancer-induced anemia in children with acute lymphoblastic leukemia receiving maintenance chemotherapy: a randomized case-controlled study.
  • PATIENT AND METHODS: This was a prospective randomized, single-center, open-label, 12-week case-control study of epoetin alfa in pediatric patients with acute lymphoblastic leukemia (ALL) in remission receiving maintenance chemotherapy.
  • Both groups were matched as regard age, sex, baseline Hb concentration, remission state, chemotherapy regimen, numbers and amount of blood transfusion, and leukemia state (both were low and standard risk).
  • [MeSH-major] Anemia / drug therapy. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Erythropoietin / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications
  • [MeSH-minor] Blood Transfusion. Child. Child, Preschool. Drug Administration Schedule. Epoetin Alfa. Female. Hemoglobins / analysis. Humans. Male. Quality of Life. Recombinant Proteins. Remission Induction. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Anemia.
  • MedlinePlus Health Information. consumer health - Anemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17852440.001).
  • [ISSN] 1607-8454
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hemoglobins; 0 / Recombinant Proteins; 11096-26-7 / Erythropoietin; 64FS3BFH5W / Epoetin Alfa
  •  go-up   go-down


70. Ettinger DS, Jotte R, Lorigan P, Gupta V, Garbo L, Conkling P, Spigel D, McNally R, Renschler M, Oliver J: Results of a phase II trial of single-agent amrubicin (AMR) in patients with extensive disease small cell lung cancer (ED-SCLC) refractory to first-line platinum-based chemotherapy: An update. J Clin Oncol; 2009 May 20;27(15_suppl):8103

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Response to 1<sup>st</sup>-line therapy was 5% complete remission (CR), 36% partial remission (PR) and 28% PD.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964280.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


71. Al-Ali HK, Wittekind C, Niederwieser D: [Complete remission of relapsed mixed cellularity Hodgkin's disease treated with rituximab]. Dtsch Med Wochenschr; 2007 Aug;132(33):1688-91
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Complete remission of relapsed mixed cellularity Hodgkin's disease treated with rituximab].
  • [Transliterated title] Komplette Remission eines rezidivierenden Hodgkin-Lymphoms vom Mischzelligen Typ nach Rituximab-Therapie.
  • Complete remission (CR) was achieved after six cycles of doxorubicin-bleomycin-vinblastin-dacarbazine (ABVD) and cyclophosphamid-vincristine-procarbazine-prednison (COPP) regimens.
  • Histology confirmed the initial diagnosis.
  • A partial remission was induced with two further DEXA-BEAM cycles (dexamethasone, BCNU [1,3-bis(2-chloroethyl)-1-nitrosourea], ectoposide, ara-C, melphalan).
  • A complete remission was achieved 2 months later.
  • A second treatment with rituximab yielded another complete remission which was maintained for 20 months.
  • In our patient the safety and efficacy of rituximab in relapsed CD20-positive classical HD of an MC type was demonstrated to achieve long-lasting remission.
  • [MeSH-minor] Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / therapeutic use. Carmustine / therapeutic use. Cyclophosphamide / therapeutic use. Cytarabine / therapeutic use. Dacarbazine / therapeutic use. Dexamethasone / therapeutic use. Doxorubicin / therapeutic use. Etoposide / therapeutic use. Humans. Lymph Nodes / pathology. Male. Melphalan / therapeutic use. Middle Aged. Peripheral Blood Stem Cell Transplantation. Prednisone / therapeutic use. Procarbazine / therapeutic use. Remission Induction / methods. Rituximab. Treatment Outcome. Vinblastine / therapeutic use. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17713864.001).
  • [ISSN] 1439-4413
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 04079A1RDZ / Cytarabine; 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; 7GR28W0FJI / Dacarbazine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q41OR9510P / Melphalan; U68WG3173Y / Carmustine; VB0R961HZT / Prednisone; ABVD protocol; COPP protocol; Dexa-BEAM protocol
  •  go-up   go-down


72. Reinfjell T, Lofstad GE, Nordahl HM, Vikan A, Diseth TH: Children in remission from acute lymphoblastic leukaemia: mental health, psychosocial adjustment and parental functioning. Eur J Cancer Care (Engl); 2009 Jul;18(4):364-70
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Children in remission from acute lymphoblastic leukaemia: mental health, psychosocial adjustment and parental functioning.
  • Children in remission from acute lymphoblastic leukaemia: mental health, psychosocial adjustment and parental functioningThe objective of this study is to assess the mental health and psychosocial adjustment of children in remission from acute lymphoblastic leukaemia (ALL), and parental functioning compared to healthy controls.
  • Children in remission from ALL showed on average significantly more problems regarding mental health and psychosocial adjustment, as reported by their parents, compared with healthy controls.
  • Adequate rehabilitation and follow-up programmes should be implemented for children in remission from ALL.
  • [MeSH-major] Adaptation, Psychological. Mental Disorders / epidemiology. Parents / psychology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / psychology
  • [MeSH-minor] Adolescent. Adult. Anxiety / epidemiology. Child. Cross-Sectional Studies. Depression / epidemiology. Female. Health Status. Humans. Male. Middle Aged. Norway. Remission Induction. Surveys and Questionnaires

  • MedlinePlus Health Information. consumer health - Child Mental Health.
  • MedlinePlus Health Information. consumer health - Mental Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19473372.001).
  • [ISSN] 1365-2354
  • [Journal-full-title] European journal of cancer care
  • [ISO-abbreviation] Eur J Cancer Care (Engl)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


73. Reinfjell T, Lofstad GE, Veenstra M, Vikan A, Diseth TH: Health-related quality of life and intellectual functioning in children in remission from acute lymphoblastic leukaemia. Acta Paediatr; 2007 Sep;96(9):1280-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Health-related quality of life and intellectual functioning in children in remission from acute lymphoblastic leukaemia.
  • AIM: To evaluate the health-related quality of life (HRQOL) and intellectual functioning of children in remission from acute lymphoblastic leukaemia (ALL).
  • Follow-up programs that target the psychosocial health of children in remission from ALL should be implemented.
  • [MeSH-major] Cognition / physiology. Health Status. Precursor Cell Lymphoblastic Leukemia-Lymphoma / psychology. Quality of Life / psychology
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Humans. Male. Neuropsychological Tests. Remission Induction. Surveys and Questionnaires

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Acta Paediatr. 2007 Sep;96(9):1265-8 [17718778.001]
  • (PMID = 17590194.001).
  • [ISSN] 0803-5253
  • [Journal-full-title] Acta paediatrica (Oslo, Norway : 1992)
  • [ISO-abbreviation] Acta Paediatr.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  •  go-up   go-down


74. Wolter A, Preuss U, Krischke N, Wong JW, Langosch JM, Zimmermann J: [Recovery and remission in schizophrenia. Results from a naturalistic 2-year follow-up inpatient study]. Fortschr Neurol Psychiatr; 2010 Aug;78(8):468-74
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Recovery and remission in schizophrenia. Results from a naturalistic 2-year follow-up inpatient study].
  • [Transliterated title] Recovery und Remission bei Schizophrenie. Ergebnisse einer naturalistischen 2-Jahres-Katamnesestudie ehemals stationärer Patienten.
  • INTRODUCTION: Remission in schizophrenia is defined as a period of at least 6 months in which symptom reduction occurs.
  • Criteria of remission for each domain were assessed using the BPRS (brief psychiatric rating scale, symptomatic remission), GAF (global assessment of functioning, functional remission) and the SWN-K (subjective well-being under neuroleptics, remission of subjective well-being).
  • Approximately one-third of the individuals had remission with a stable quality of life.
  • CONCLUSION: Compared to previous studies, the rates of remission and recovery in the current sample were quite low.
  • [MeSH-minor] Adult. Age of Onset. Antipsychotic Agents / therapeutic use. Female. Follow-Up Studies. Humans. Inpatients. Longitudinal Studies. Male. Middle Aged. Prospective Studies. Psychiatric Status Rating Scales. Quality of Life. Recovery of Function. Remission, Spontaneous

  • Genetic Alliance. consumer health - Schizophrenia.
  • MedlinePlus Health Information. consumer health - Schizophrenia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) Georg Thieme Verlag KG Stuttgart--New York.
  • (PMID = 20694939.001).
  • [ISSN] 1439-3522
  • [Journal-full-title] Fortschritte der Neurologie-Psychiatrie
  • [ISO-abbreviation] Fortschr Neurol Psychiatr
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antipsychotic Agents
  •  go-up   go-down


75. Ortmann J, Schiffl H, Lang SM: [Partial clinical remission of chronic IgA nephropathy with therapy of tuberculosis]. Dtsch Med Wochenschr; 2010 Jun;135(24):1228-31
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Partial clinical remission of chronic IgA nephropathy with therapy of tuberculosis].
  • [Transliterated title] Partielle klinische Remission einer chronischen IgA-Nephropathie unter antituberkulotischer Therapie.
  • INVESTIGATIONS: The diagnosis of the underlying etiology of the pleural effusions was difficult in spite of a thorough diagnostic work-up.
  • CONCLUSIONS: This report of a partial remission of IgA nephropathy by treatment of pleural tuberculosis supports the hypothesis that there may be a causal relationship between mycobacterial infections and IgA nephropathy.
  • [MeSH-minor] Adult. Biopsy. Drug Therapy, Combination. Humans. Kidney / pathology. Male. Pleural Effusion / diagnosis. Pleural Effusion / drug therapy. Pleural Effusion / etiology. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Tuberculosis.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Georg Thieme Verlag KG Stuttgart New York.
  • (PMID = 20533156.001).
  • [ISSN] 1439-4413
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antitubercular Agents
  •  go-up   go-down


76. Ostendorf B, Scherer A, Kellner H, Backhaus M: [Project REMISSION(PLUS): clinical and radiological remission : new treatment goals in the management of rheumatoid arthritis]. Z Rheumatol; 2008 Dec;67(8):707-10, 712-5
MedlinePlus Health Information. consumer health - Ultrasound.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Project REMISSION(PLUS): clinical and radiological remission : new treatment goals in the management of rheumatoid arthritis].
  • [Transliterated title] Projekt REMISSION(PLUS): klinische und radiologische Remission : Neue Therapieziele in der Behandlung der rheumatoiden Arthritis.
  • The REMISSION(PLUS) initiative aspire to integrate modern imaging technologies as standard methods in the care and management of RA patients.
  • The main areas on which this initiative will be focusing are the conceptualization and implementation of educational programs and training seminars on sonography and MRI, the development and establishment of case report forms for standardized documentation of findings, and the systematic monitoring of patients on treatment, with the aim of producing very precise documentation of structural change processes in RA and also, if possible, to document radiological remission or even progression.
  • The REMISSION(PLUS) project also includes the setting up of specialized centers of excellence, which will network to support the implementation and access to the various imaging procedures at hospitals, rheumatology clinics and rheumatology practices nationwide.
  • [MeSH-major] Arthritis, Rheumatoid / diagnosis. Arthrography. Magnetic Resonance Imaging. Patient Care Team. Ultrasonography
  • [MeSH-minor] Documentation. Follow-Up Studies. Humans. Joints / pathology. Remission Induction. Synovial Membrane / pathology. Synovitis / diagnosis. Synovitis / therapy


77. Wolf P: [Epilepsy as a dynamic condition: facilitation and inhibition, establishment and remission]. Ugeskr Laeger; 2005 Oct 10;167(41):3865-7
MedlinePlus Health Information. consumer health - Epilepsy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Epilepsy as a dynamic condition: facilitation and inhibition, establishment and remission].
  • [Transliterated title] Epilepsi som dynamisk tilstand: fremme og haemning af anfald, etablering og remission.
  • Some of these are known, and their action can best be observed at onset, when seizure repetition is established or prevented, and at remission, when the decline of the antiepileptic drug therapeutic threshold reflects a fall in the propensity to seizures.
  • [MeSH-minor] Anticonvulsants / therapeutic use. Humans. Models, Biological. Remission, Spontaneous

  • Genetic Alliance. consumer health - Epilepsy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16221424.001).
  • [ISSN] 1603-6824
  • [Journal-full-title] Ugeskrift for laeger
  • [ISO-abbreviation] Ugeskr. Laeg.
  • [Language] dan
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Anticonvulsants
  •  go-up   go-down


78. Petruskevicius I, Bukh A, Mertz H, Johnsen HE: [Complete remission after Rituximab treatment in refractory hairy cell leukemia]. Ugeskr Laeger; 2008 Jun 23;170(26-32):2350
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Complete remission after Rituximab treatment in refractory hairy cell leukemia].
  • [Transliterated title] Komplet remission efter rituximabbehandling ved refraktaer hårcelleleukaemi.
  • A 40 year-old man with hairy cell leukemia (HCL) was treated with Cladribin, but achieved only partial response (PR).
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Leukemia, Hairy Cell / drug therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived. Humans. Male. Neoplasm Recurrence, Local. Remission Induction. Rituximab

  • Genetic Alliance. consumer health - Hairy Cell Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18570771.001).
  • [ISSN] 1603-6824
  • [Journal-full-title] Ugeskrift for laeger
  • [ISO-abbreviation] Ugeskr. Laeg.
  • [Language] dan
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


79. Pories W: [Type II diabetes. Permanent remission by surgery of the foregut]. Chirurg; 2009 May;80(5):416, 418-21
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Type II diabetes. Permanent remission by surgery of the foregut].
  • [Transliterated title] Typ-II-Diabetes : Dauerhafte Remission durch Chirurgie des Foregut.
  • Bariatric surgery offers a safe and effective treatment of type II diabetes for morbidly obese persons with complete and permanent remission as well as a clear reduction in mortality.

  • Genetic Alliance. consumer health - Diabetes.
  • MedlinePlus Health Information. consumer health - Diabetes Type 2.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Obes Surg. 2009 Mar;19(3):307-12 [18987919.001]
  • [Cites] Obes Surg. 2007 Oct;17(10):1332-9 [18098400.001]
  • [Cites] Ann Surg. 2006 Nov;244(5):741-9 [17060767.001]
  • [Cites] Surg Obes Relat Dis. 2006 Sep-Oct;2(5):497-503; discussion 503 [17015199.001]
  • [Cites] Ann Surg. 1998 May;227(5):637-43; discussion 643-4 [9605655.001]
  • [Cites] N Engl J Med. 2006 Oct 12;355(15):1593-602 [17035653.001]
  • [Cites] Ann Surg. 1987 Sep;206(3):316-23 [3632094.001]
  • [Cites] Surg Obes Relat Dis. 2007 Mar-Apr;3(2):195-7 [17386401.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Dec;93(12):4656-63 [18765510.001]
  • [Cites] Ann Surg. 2003 Oct;238(4):467-84; discussion 84-5 [14530719.001]
  • [Cites] Ann Surg. 1995 Sep;222(3):339-50; discussion 350-2 [7677463.001]
  • [Cites] J Gastrointest Surg. 1997 May-Jun;1(3):213-20; discussion 220 [9834350.001]
  • [Cites] Obes Res. 1996 May;4(3):316-9 [8732969.001]
  • [Cites] JAMA. 2008 Jan 23;299(3):316-23 [18212316.001]
  • [Cites] N Engl J Med. 2007 Aug 23;357(8):741-52 [17715408.001]
  • [Cites] N Engl J Med. 2007 Aug 23;357(8):753-61 [17715409.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Jul;93(7):2479-85 [18430778.001]
  • (PMID = 19440748.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Incretins
  • [Number-of-references] 22
  •  go-up   go-down


80. Haas A, Lobeck H, Hummel M, Maschmeyer G: [Prolonged remission after immunotherapy of a previously refractory peripheral T-cell non-Hodgkin lymphoma]. Dtsch Med Wochenschr; 2006 Oct 27;131(43):2386-9
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prolonged remission after immunotherapy of a previously refractory peripheral T-cell non-Hodgkin lymphoma].
  • [Transliterated title] Anhaltende Remission nach Immuntherapie bei zuvor refraktärem peripherem T-Non-Hodgkin-Lymphom.
  • The follow up CT-scans one year after treatment showed a stable remission.
  • CONCLUSION: In T-NHL with primary non-response it is especially difficult to induce a stable remission.
  • Despite a course which was complicated by infections and a failing response to increased chemotherapy a remission was achieved in this patient with a monotherapy of alemtuzumab for eight weeks without complications, followed by radiotherapy.
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Etoposide / therapeutic use. Female. Germany. Granulocyte Colony-Stimulating Factor / therapeutic use. Humans. L-Lactate Dehydrogenase / blood. Middle Aged. Neoplasm Staging. Prednisolone / therapeutic use. Radiotherapy, Adjuvant. Recombinant Proteins. Remission Induction. Tomography, X-Ray Computed. Treatment Outcome. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17054053.001).
  • [ISSN] 0012-0472
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 0 / Recombinant Proteins; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 3A189DH42V / alemtuzumab; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; EC 1.1.1.27 / L-Lactate Dehydrogenase; CHOEP protocol
  •  go-up   go-down


81. Mantadakis E, Anagnostatou N, Danilatou V, Markaki EA, Spanaki AM, Briassoulis G, Kalmanti M: Fulminant hepatitis due to varicella zoster virus in a girl with acute lymphoblastic leukemia in remission: report of a case and review. J Pediatr Hematol Oncol; 2005 Oct;27(10):551-3
MedlinePlus Health Information. consumer health - Chickenpox.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fulminant hepatitis due to varicella zoster virus in a girl with acute lymphoblastic leukemia in remission: report of a case and review.
  • The authors describe a 4-year-old girl with acute lymphoblastic leukemia in remission who developed fulminant hepatic failure due to varicella-zoster virus (VZV).
  • [MeSH-major] Chickenpox / virology. Hepatitis, Viral, Human / virology. Herpesvirus 3, Human / isolation & purification. Liver Failure, Acute / virology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / physiopathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child, Preschool. Fatal Outcome. Female. Humans. Immunocompromised Host. Remission Induction

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Hepatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16217259.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. Mitsuishi T, Iida K, Kawana S: Papulonecrotic tuberculid with spontaneous remission. J Dermatol; 2006 Feb;33(2):112-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Papulonecrotic tuberculid with spontaneous remission.
  • We describe a 62-year-old Japanese woman who had skin lesions involving her extremities, chest and back that showed spontaneous remission.
  • [MeSH-minor] Biopsy, Needle. Female. Humans. Immunohistochemistry. Japan. Middle Aged. Rare Diseases. Remission, Spontaneous. Risk Assessment

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16556278.001).
  • [ISSN] 0385-2407
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


83. Ranganath VK, Khanna D, Paulus HE: ACR remission criteria and response criteria. Clin Exp Rheumatol; 2006 Nov-Dec;24(6 Suppl 43):S-14-21
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ACR remission criteria and response criteria.
  • Many clinical studies now are geared toward evaluating the concept of eradicating inflammation as a method to seek the elusive goal of sustained remission in RA.
  • One of the first descriptions of remission in 'RA' was by Short et al in 1948, when he documented the natural progression of the disease.
  • Since that time, various criteria have been developed to define RA remission utilizing clinical, radiographic, and laboratory measures.
  • The most stringent of criteria is the American College of Rheumatology Remission Criteria, developed in 1980, which consists of clinical symptoms and signs of inflammation including fatigue, joint pain, morning stiffness, joint tenderness, joint swelling, and erythrocyte sedimentation rate (ESR).
  • Several reports have compared ACR remission criteria to Disease Activity Score (DAS) values to identify equivalent DAS remission values, and these have been extrapolated to modified versions of the DAS, the Simple Disease Activity Index (SDAI), and Clinical Disease Activity Index (CDAI).
  • The ACR remission criteria and the response measures were not designed for use as the target or goal for the clinical management of individual RA patients in routine clinical practice.
  • Nevertheless, rheumatologists yearn for the eradication of inflammation in all RA patients, and attaining remission may be achievable in the future.
  • [MeSH-minor] Clinical Trials as Topic. Female. Humans. Male. Practice Guidelines as Topic / standards. Remission Induction. Research Design. Severity of Illness Index

  • MedlinePlus Health Information. consumer health - Rheumatoid Arthritis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17083757.001).
  • [ISSN] 0392-856X
  • [Journal-full-title] Clinical and experimental rheumatology
  • [ISO-abbreviation] Clin. Exp. Rheumatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antirheumatic Agents
  • [Number-of-references] 52
  •  go-up   go-down


84. Narasimhan M, Kannaday MH: Treating depression and achieving remission. Asian J Psychiatr; 2010 Dec;3(4):163-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treating depression and achieving remission.
  • Despite all the advances in understanding the biological underpinnings of depression and the extensive armamentarium of antidepressants remission is a difficult goal to achieve.
  • There are several hurdles to achieving remission including accuracy of diagnosis, partial response, suboptimization of the medication, and failure to capture residual symptoms.
  • There is an urgent need to implement strategies to achieve remission including destigmatizing mental illness, educating patients, their families, optimizing treatments, exploring novel interventions and addressing residual symptoms.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010. Published by Elsevier B.V.
  • (PMID = 23050881.001).
  • [ISSN] 1876-2026
  • [Journal-full-title] Asian journal of psychiatry
  • [ISO-abbreviation] Asian J Psychiatr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


85. Schimmele CM, Wu Z, Penning MJ: Gender and remission of mental illness. Can J Public Health; 2009 Sep-Oct;100(5):353-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gender and remission of mental illness.
  • The objective of this study was to determine whether gender also influences the timing of remission from illness.
  • The regression analysis undertaken considered remission in terms of all ICD-9 mental disorders (codes 290-314).
  • This analysis compares males and females on average length of treatment for mental illness and examines whether any gender differences in remission are generalized or disorder specific.
  • The target population represented all individuals with an ICD-9 diagnosis of mental illness who were treated through the Medical Services Plan in British Columbia.
  • RESULTS: There was a non-significant bivariate relation between gender and the timing of remission from mental illness.
  • However, the multivariate findings demonstrated that a significant gender effect on remission emerges after controls were introduced for demographic and socio-economic characteristics.
  • In particular, the timing of remission was somewhat longer for females.
  • CONCLUSIONS: The emergence of a significant effect after considering demographic and socio-economic characteristics suggests that a social disadvantage within the male sample (more single males) was suppressing a small negative effect of female gender on the timing of remission.
  • In other words, a social disadvantage among males concealed an unexplained female disadvantage in remission.

  • Genetic Alliance. consumer health - Mental Illness.
  • MedlinePlus Health Information. consumer health - Mental Disorders.
  • MedlinePlus Health Information. consumer health - Mental Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19994736.001).
  • [ISSN] 0008-4263
  • [Journal-full-title] Canadian journal of public health = Revue canadienne de sante publique
  • [ISO-abbreviation] Can J Public Health
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / R24 HD042828; None / None / / R24 HD042828-10; United States / NICHD NIH HHS / HD / R24 HD042828-10; Canada / Canadian Institutes of Health Research / /
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  •  go-up   go-down


86. Tsuji A, Sasaki M, Ishii T, Sato S, Kanki H, Suzuki S, Takeuchi S, Fukuda T: Persistent eosinophilic infiltration of the myocardium in a child in complete remission of acute lymphoblastic leukemia and eosinophilia. Potential role in late cardiac disease? Keio J Med; 2010;59(2):64-8
MedlinePlus Health Information. consumer health - Eosinophilic Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Persistent eosinophilic infiltration of the myocardium in a child in complete remission of acute lymphoblastic leukemia and eosinophilia. Potential role in late cardiac disease?
  • This report describes the long-term (23 years) follow-up of a pediatric patient with acute lymphoblastic leukemia and eosinophilia who underwent multiple valve replacements.
  • An 8-year-old boy with this complex disease was admitted in January 1984 and treated with 6-week course of vincristine, L-asparaginase, and prednisolone, which induced complete remission.
  • The present study indicates that a subset of patients in complete remission of acute lymphoblastic leukemia and eosinophilia can show persistent myocardial eosinophilic infiltration and are at risk of late cardiac disease.
  • [MeSH-major] Cardiomyopathies / etiology. Cardiomyopathies / pathology. Eosinophilia / complications. Eosinophilia / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Cardiomyopathy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20601842.001).
  • [ISSN] 1880-1293
  • [Journal-full-title] The Keio journal of medicine
  • [ISO-abbreviation] Keio J Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


87. Foghsgaard S, Kjaergård HK: [Total remission of hemiparesis after operation in acute aortic dissection]. Ugeskr Laeger; 2008 May 5;170(19):1650-1
MedlinePlus Health Information. consumer health - Aortic Aneurysm.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Total remission of hemiparesis after operation in acute aortic dissection].
  • [Transliterated title] Fuldstaendig remission af hemiparese efter operation for akut proksimal aortadissektion.
  • Cerebral ischaemia might not preclude operation in acute aortic dissection.
  • A 37-year-old male with an acute proximal aortic dissection (type A) and coma and hemiparesis caused by involvement of the arch vessels and secondary brain malperfusion underwent emergency surgical repair with replacement of the ascending aorta in profound circulatory arrest.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18489876.001).
  • [ISSN] 1603-6824
  • [Journal-full-title] Ugeskrift for laeger
  • [ISO-abbreviation] Ugeskr. Laeg.
  • [Language] dan
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


88. Degmecić D, Pozgain I, Filaković P, Dodig-Curković K, Mihanović M: Psychopharmacotherapy and remission of patients with schizophrenia. Coll Antropol; 2009 Jun;33(2):547-51
MedlinePlus Health Information. consumer health - Schizophrenia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Psychopharmacotherapy and remission of patients with schizophrenia.
  • Schizophrenia is a clinical syndrome of variable, but profoundly disruptive, psychopathology that involves cognition, emotion, perception and other aspects of behavior The Remission in Schizophrenia Working Group (RSWG) has defined criteria for symptomatic remission based on achieving and maintaining a consistently low symptom threshold for at least six consecutive months.
  • Aim of our study was to determine which antipsychotic are used in the treatment of patients with schizophrenia, as well as to assess are there differences between patients treated with typical and atypical antipsychotics and how many of them are in remission according to the defined remission criteria.
  • All of them were assessed with specially designed questionnaire about sociodemographic data, than with 8 item of PANSS (remission criteria), and with Clinical Global Impression scale.
  • Authors did not found statistically significant differences in two groups of patients regarding the scores on PANSS, CGI and number of patients in remission.
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Psychopharmacology. Remission Induction. Surveys and Questionnaires

  • Genetic Alliance. consumer health - Schizophrenia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19662777.001).
  • [ISSN] 0350-6134
  • [Journal-full-title] Collegium antropologicum
  • [ISO-abbreviation] Coll Antropol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Croatia
  • [Chemical-registry-number] 0 / Antipsychotic Agents
  •  go-up   go-down


89. Bannowsky A, Wefer B, Naumann M, Hamann M, Hautmann S, Jünemann KP: ["Second line" polychemotherapy in metastatic urothelial cancer of the renal pelvis. Persisting partial remission by 18 treatment cycles of gemcitabine/paclitaxel after 24 treatment cycles gemcitabine/cisplatin "stable disease"]. Urologe A; 2005 Aug;44(8):915-7
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ["Second line" polychemotherapy in metastatic urothelial cancer of the renal pelvis. Persisting partial remission by 18 treatment cycles of gemcitabine/paclitaxel after 24 treatment cycles gemcitabine/cisplatin "stable disease"].
  • [Transliterated title] "Second-line-Polychemotherapie" beim metastasierten Urothelkarzinom des Nierenbeckens. Andauernde partielle Remission nach 18 Kursen Gemcitabin/Paclitaxel trotz 24 Kursen Gemcitabin/Cisplatin im "stable disease".
  • We report an interesting case of a 59-year-old man suffering from urothelial cancer of the renal pelvis with pulmonary, lymphogenous, and bone metastases who had an unexpected response to "second-line" chemotherapy with only 2 treatment cycles of gemcitabine/paclitaxel (partial remission) after 24 treatment cycles of gemcitabine/cisplatin in "stable disease" with progression between the therapeutic intervals.
  • [MeSH-minor] Chemotherapy, Adjuvant. Combined Modality Therapy. Disease Progression. Drug Administration Schedule. Drug Resistance, Neoplasm. Humans. Male. Middle Aged. Remission Induction. Retroperitoneal Neoplasms / diagnostic imaging. Retroperitoneal Neoplasms / drug therapy. Retroperitoneal Neoplasms / secondary. Tomography, X-Ray Computed


90. Rolfe VE, Fortun PJ, Hawkey CJ, Bath-Hextall F: Probiotics for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev; 2006;(4):CD004826
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Probiotics for maintenance of remission in Crohn's disease.
  • BACKGROUND: Crohn's disease (CD) is characterised by episodes of disease activity and symptom-free remission.
  • OBJECTIVES: To assess the effectiveness of probiotics for the maintenance of remission in CD.
  • There was no statistically significant benefit of E. coli Nissle for reducing the risk of relapse compared to placebo (RR 0.43, 95% CI 0.15 to 1.20), or Lactobacillus GG after surgically-induced remission (RR 1.58, 95% CI 0.30 to 8.40) or medically-induced remission (RR 0.83, 95% CI 0.25 to 2.80).
  • AUTHORS' CONCLUSIONS: There is no evidence to suggest that probiotics are beneficial for the maintenance of remission in CD.
  • [MeSH-minor] Adult. Child. Humans. Randomized Controlled Trials as Topic. Remission Induction

  • Genetic Alliance. consumer health - Crohn Disease.
  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17054217.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] England
  • [Number-of-references] 50
  •  go-up   go-down


91. Mäkinen H, Kautiainen H, Hannonen P, Sokka T: Is DAS28 an appropriate tool to assess remission in rheumatoid arthritis? Ann Rheum Dis; 2005 Oct;64(10):1410-3
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is DAS28 an appropriate tool to assess remission in rheumatoid arthritis?
  • OBJECTIVES: To study which cut off point of DAS28 corresponds to fulfilment of the American Rheumatism Association (ARA) preliminary remission criteria, and clinical remission criteria in patients with rheumatoid arthritis (RA).
  • METHODS: All adult patients diagnosed with RA at Jyväskylä Central Hospital 1997-98 were assessed for remission at 5 years.
  • Remission was defined as (a) ARA remission;.
  • (b) clinical remission (defined as no tender or swollen joints and normal erythrocyte sedimentation rate).
  • A receiver operating characteristics curve analysis was performed to calculate a cut off point of DAS28 that best corresponds to the ARA remission criteria and the clinical remission criteria.
  • At 5 years, 19 (12%) patients met the ARA remission criteria, and 55 (34%) met the clinical remission criteria.
  • The cut off value of DAS28 was 2.32 for the ARA remission criteria, and 2.68 for the clinical remission criteria.
  • CONCLUSION: In this study the DAS28 cut off point for the ARA remission was lower than in previous studies.
  • The cut off point for DAS28 remission remains controversial.
  • A substantial proportion of patients below the DAS28 cut off point for remission have tender or swollen joints, or both.
  • DAS28 may not be an appropriate tool for assessment of remission in RA.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Blood Sedimentation. Female. Humans. Male. Middle Aged. Predictive Value of Tests. ROC Curve. Remission Induction. Treatment Outcome


92. Yoruk A, Erguven M, Celiker E, Aki H, Timur C, Yuksel E, Ozkan H: Spontaneous remission of acute lymphoblastic leukemia with mediastinal mass. Pediatr Hematol Oncol; 2008 Apr-May;25(3):181-6
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous remission of acute lymphoblastic leukemia with mediastinal mass.
  • Spontaneous remission/regression of cancer is defined as partial or complete disappearance of malignant disease temporarily or permanently in the absence of medical treatment.
  • This event is named as spontaneous regression for solid tumors and spontaneous remission for leukemia.
  • The authors report the case of a girl aged 4 years and 3 months, who presented with mediastinal mass and leukemic findings in the bone marrow both of which reappeared after spontaneous regression and remission, respectively.
  • [MeSH-major] Mediastinal Neoplasms. Neoplasm Regression, Spontaneous. Precursor Cell Lymphoblastic Leukemia-Lymphoma

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18432500.001).
  • [ISSN] 1521-0669
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


93. Sesin CA, Bingham CO 3rd: Remission in rheumatoid arthritis: wishful thinking or clinical reality? Semin Arthritis Rheum; 2005 Dec;35(3):185-96
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Remission in rheumatoid arthritis: wishful thinking or clinical reality?
  • OBJECTIVES: To review the concept of remission in rheumatoid arthritis (RA), as defined by the Food and Drug Administration (FDA), the American College of Rheumatology (ACR), and the European League Against Rheumatism (EULAR).
  • To delineate differences between significant clinical improvements, very low disease activity, and the achievement of true remission.
  • METHODS: The MEDLINE database was searched for the key words "remission" and "rheumatoid arthritis."
  • We review 3 well-defined sets of criteria established by the ACR, EULAR, and the FDA for measuring remission.
  • RESULTS: Defining remissions in clinical trials and clinical practice requires appropriate standardized and objective outcome measures, such as the ACR and EULAR remission criteria.
  • Remission, as defined by the ACR criteria, has been observed in 7 to 22% of patients treated with traditional DMARD monotherapy (ie, gold, penicillamine, methotrexate [MTX], cyclosporine A, or sulfasalazine), but these remissions have often been short-lived.
  • Treatments with DMARD combinations, biologic monotherapy, and biologic combination therapy with MTX offer greater hope and may facilitate the higher rates of remission.
  • Clinical trial results have shown that newer DMARDs such as leflunomide or the combination of multiple DMARDs can generally elicit greater EULAR remission rates (ranging from 13 to 42%) than monotherapies.
  • Biologic combinations with MTX have also been shown to induce significant remission (as defined by the EULAR criteria) in RA patients, with a 31% rate observed with infliximab plus MTX at 54 weeks, a 50% rate observed for adalimumab plus MTX after 2 years of therapy, and a 41% rate observed for etanercept plus MTX after 2 years of therapy.
  • CONCLUSIONS: In the era of biologics and combination therapy, identifying remission or at least very low disease activity as the ultimate goal in RA therapy should become the new standard for the outcome of all RA trials.
  • [MeSH-minor] Clinical Trials as Topic. Humans. Practice Guidelines as Topic. Remission Induction. Retrospective Studies. Severity of Illness Index. Treatment Outcome

  • Genetic Alliance. consumer health - Arthritis.
  • Genetic Alliance. consumer health - Rheumatoid arthritis.
  • MedlinePlus Health Information. consumer health - Rheumatoid Arthritis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16325659.001).
  • [ISSN] 0049-0172
  • [Journal-full-title] Seminars in arthritis and rheumatism
  • [ISO-abbreviation] Semin. Arthritis Rheum.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antirheumatic Agents
  •  go-up   go-down


94. Aletaha D, Smolen JS: Remission of rheumatoid arthritis: should we care about definitions? Clin Exp Rheumatol; 2006 Nov-Dec;24(6 Suppl 43):S-45-51
MedlinePlus Health Information. consumer health - Rheumatoid Arthritis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Remission of rheumatoid arthritis: should we care about definitions?
  • A state of remission can be achieved in more and more rheumatoid arthritis (RA) patients.
  • Remission can be defined by two different approaches: one using a categorical model, requiring criteria for multiple variables to be fulfilled, each with its own threshold value (remission "criteria"); the other using a dimensional model, providing single measures of activity, which allow definition of remission by a single cut point (remission cut points for composite indices).
  • The face validity of remission as defined by composite indices surpasses the one for the "criteria".
  • Likewise, the ones that are not weighted seem to surpass the weighted ones, as can be seen by the significant proportion of patients that continues to have considerable swollen joint counts despite being in Disease Activity Score (DAS)-28 remission.
  • All composite indices seem to perform similarly well as tests for remission using expert judgments as the gold standard.
  • [MeSH-minor] Humans. Patient Satisfaction. Recovery of Function. Reference Values. Remission Induction

  • Genetic Alliance. consumer health - Arthritis.
  • Genetic Alliance. consumer health - Rheumatoid arthritis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17083763.001).
  • [ISSN] 0392-856X
  • [Journal-full-title] Clinical and experimental rheumatology
  • [ISO-abbreviation] Clin. Exp. Rheumatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 39
  •  go-up   go-down


95. Valesini G, Di Franco M, Spinelli FR, Scrivo R: Induction of remission in rheumatoid arthritis: criteria and opportunities. Rheumatol Int; 2008 Dec;29(2):131-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction of remission in rheumatoid arthritis: criteria and opportunities.
  • The concept of remission in rheumatology is complicated by the lack of a single gold standard measurement, spontaneous remissions and the usage of several sets of remission criteria.
  • Feasibility is reduced by traditional clinical practice, which does not include remission criteria monitoring.
  • Remission is important to prevent joint destruction, preserve adequate quality of life and prevent disability.
  • [MeSH-minor] Disability Evaluation. Drug Therapy, Combination. Humans. Quality of Life. Randomized Controlled Trials as Topic. Remission Induction. Treatment Outcome

  • Genetic Alliance. consumer health - Arthritis.
  • Genetic Alliance. consumer health - Rheumatoid arthritis.
  • MedlinePlus Health Information. consumer health - Rheumatoid Arthritis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arthritis Rheum. 2006 Dec;54(12 ):3761-73 [17133543.001]
  • [Cites] Rheumatology (Oxford). 2006 Dec;45(12):1558-65 [16705046.001]
  • [Cites] Ann Rheum Dis. 2007 Nov;66 Suppl 3:iii2-22 [17934088.001]
  • [Cites] Arthritis Rheum. 2006 Jan;54(1):26-37 [16385520.001]
  • [Cites] Ann Rheum Dis. 2004 Jun;63(6):675-80 [15140774.001]
  • [Cites] Arthritis Res Ther. 2006;8(4):216 [16879719.001]
  • [Cites] J Rheumatol. 2004 Jan;31(1):58-65 [14705219.001]
  • [Cites] Lancet. 1997 Aug 2;350(9074):309-18 [9251634.001]
  • [Cites] Arthritis Rheum. 2002 Feb;46(2):328-46 [11840435.001]
  • [Cites] Arthritis Rheum. 2002 Apr;46(4):894-8 [11953964.001]
  • [Cites] Ann Rheum Dis. 2008 Aug;67(8):1096-103 [18055472.001]
  • [Cites] Scand J Rheumatol. 2005 Sep-Oct;34(5):333-41 [16234180.001]
  • [Cites] Arthritis Rheum. 2006 Apr;54(4):1063-74 [16572441.001]
  • [Cites] Rheum Dis Clin North Am. 2005 Nov;31(4):729-44 [16287594.001]
  • [Cites] Ann Rheum Dis. 2005 Sep;64(9):1350-2 [15760927.001]
  • [Cites] Scand J Rheumatol. 2006 May-Jun;35(3):175-81 [16766363.001]
  • [Cites] Lancet. 2004 Jul 17-23;364(9430):263-9 [15262104.001]
  • [Cites] Joint Bone Spine. 2006 Jul;73(4):433-41 [16798046.001]
  • [Cites] Semin Arthritis Rheum. 2005 Jun;34(6):819-36 [15942917.001]
  • [Cites] Clin Exp Rheumatol. 2006 Jul-Aug;24(4):413-23 [16956432.001]
  • [Cites] Clin Exp Rheumatol. 2006 Nov-Dec;24(6 Suppl 43):S-22-8 [17083758.001]
  • [Cites] Arthritis Rheum. 2006 Sep;54(9):2793-806 [16947627.001]
  • [Cites] J Rheumatol. 2003 Dec;30(12):2572-9 [14719196.001]
  • [Cites] Ann Rheum Dis. 2004 Jun;63(6):627-33 [15140767.001]
  • [Cites] Semin Arthritis Rheum. 2005 Dec;35(3):185-96 [16325659.001]
  • [Cites] Ann Rheum Dis. 2007 Jan;66(1):34-45 [16396980.001]
  • [Cites] Arthritis Rheum. 2004 Nov;50(11):3432-43 [15529377.001]
  • [Cites] J Rheumatol. 2005 May;32(5):796-800 [15868611.001]
  • [Cites] Ann Rheum Dis. 2006 May;65(5):637-41 [16219709.001]
  • [Cites] Lancet. 1999 May 8;353(9164):1568-73 [10334255.001]
  • [Cites] Ann Intern Med. 2007 Mar 20;146(6):406-15 [17371885.001]
  • [Cites] Ann Rheum Dis. 2002 Apr;61(4):351-3 [11874840.001]
  • [Cites] Arthritis Rheum. 2006 Jun;54(6):1786-94 [16736520.001]
  • [Cites] Ann Intern Med. 2006 Jun 20;144(12 ):865-76 [16785475.001]
  • [Cites] Clin Exp Rheumatol. 2006 Nov-Dec;24(6 Suppl 43):S-37-40 [17083761.001]
  • [Cites] Ann Rheum Dis. 2007 Jan;66(1):46-52 [17158139.001]
  • [Cites] Curr Opin Rheumatol. 2003 May;15(3):185-92 [12707569.001]
  • [Cites] Eur J Clin Pharmacol. 2006 Nov;62(11):933-7 [16932953.001]
  • [Cites] Clin Exp Rheumatol. 2006 Nov-Dec;24(6 Suppl 43):S-1-6 [17083755.001]
  • [Cites] N Engl J Med. 2005 Sep 15;353(11):1114-23 [16162882.001]
  • [Cites] Arthritis Rheum. 2000 Jan;43(1):22-9 [10643696.001]
  • [Cites] Clin Exp Rheumatol. 2006 Nov-Dec;24(6 Suppl 43):S-45-51 [17083763.001]
  • [Cites] Clin Exp Rheumatol. 2006 Nov-Dec;24(6 Suppl 43):S-7-13 [17083756.001]
  • [Cites] Ann Rheum Dis. 2005 Jan;64(1):38-43 [15130899.001]
  • (PMID = 18807254.001).
  • [ISSN] 0172-8172
  • [Journal-full-title] Rheumatology international
  • [ISO-abbreviation] Rheumatol. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antirheumatic Agents
  • [Number-of-references] 46
  •  go-up   go-down


96. Boguth K, Schenk L: [New-onset urinary incontinence in the first six month after admission into a nursing home: prevalence, incidence and remission, risk and protective factors]. Z Gerontol Geriatr; 2008 Aug;41(4):274-82
MedlinePlus Health Information. consumer health - Urinary Incontinence.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [New-onset urinary incontinence in the first six month after admission into a nursing home: prevalence, incidence and remission, risk and protective factors].
  • [Transliterated title] Neuerkrankung an Harninkontinenz in den ersten sechs Monaten nach dem Heimeintritt: Prävalenz, Inzidenz und Remission, Risiko und Schutzfaktoren.

  • Genetic Alliance. consumer health - Incontinence.
  • MedlinePlus Health Information. consumer health - Nursing Homes.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Geriatr Soc. 1990 Apr;38(4):433-9 [2109766.001]
  • [Cites] J Am Geriatr Soc. 1997 Feb;45(2):179-84 [9033516.001]
  • [Cites] J Am Geriatr Soc. 1993 Oct;41(10):1083-9 [8409154.001]
  • [Cites] Nurs Res. 2007 Mar-Apr;56(2):97-107 [17356440.001]
  • [Cites] J Clin Nurs. 2008 Sep;17(18):2490-6 [18266844.001]
  • [Cites] J Am Geriatr Soc. 2006 Sep;54(9):1325-33 [16970638.001]
  • [Cites] Baillieres Best Pract Res Clin Obstet Gynaecol. 2000 Apr;14(2):183-205 [10897319.001]
  • [Cites] Urology. 2006 Feb;67(2):281-7 [16461078.001]
  • [Cites] J Gerontol. 1987 Nov;42(6):631-7 [3680883.001]
  • [Cites] J Gerontol A Biol Sci Med Sci. 2001 Jan;56(1):M14-8 [11193226.001]
  • [Cites] Neurourol Urodyn. 2004;23(3):211-22 [15098216.001]
  • [Cites] BMJ. 1995 Oct 21;311(7012):1063-4 [7580664.001]
  • [Cites] Age Ageing. 2003 Mar;32(2):194-9 [12615564.001]
  • [Cites] Urology. 2000 Aug 1;56(2):245-9 [10925087.001]
  • [Cites] Res Nurs Health. 1991 Dec;14(6):405-12 [1792342.001]
  • [Cites] Wien Med Wochenschr. 1998;148(13):305-8 [9757516.001]
  • (PMID = 18677627.001).
  • [ISSN] 0948-6704
  • [Journal-full-title] Zeitschrift fur Gerontologie und Geriatrie
  • [ISO-abbreviation] Z Gerontol Geriatr
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


97. Wunderink L, Nienhuis FJ, Sytema S, Wiersma D: Predictive validity of proposed remission criteria in first-episode schizophrenic patients responding to antipsychotics. Schizophr Bull; 2007 May;33(3):792-6
MedlinePlus Health Information. consumer health - Schizophrenia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictive validity of proposed remission criteria in first-episode schizophrenic patients responding to antipsychotics.
  • The objective of this study was to examine the predictive validity of the remission criteria proposed by Andreasen et al in first-episode patients responding to antipsychotics.
  • Antipsychotic responsive patients with first-episode schizophrenia showing symptom remission (n = 60) were compared with patients who did not fulfill the proposed criteria (n = 65).
  • Patients in the remission group showed a significantly better outcome during follow-up on all Positive and Negative Syndrome Scale subscale scores (positive, negative, and general symptom subscales) and a significantly higher level of social functioning.
  • The proposed multidimensional criteria for symptomatic remission convey significant information when applied to first-episode patients who responded to antipsychotics, predicting outcome on the domains of both psychopathology and social functioning.
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Female. Humans. Longitudinal Studies. Male. Middle Aged. Netherlands. Prognosis. Psychiatric Status Rating Scales / statistics & numerical data. Psychometrics. Quality of Life. Social Adjustment. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Psychiatr Scand. 2006 Apr;113(4):332-9 [16638078.001]
  • [Cites] Acta Psychiatr Scand. 2006 Feb;113(2):91-5 [16423159.001]
  • [Cites] Qual Life Res. 2000 Feb;9(1):121-4 [10981212.001]
  • [Cites] Br J Psychiatry. 2001 Jun;178:506-17 [11388966.001]
  • [Cites] Schizophr Bull. 2002;28(2):203-22 [12693428.001]
  • [Cites] Am J Psychiatry. 2004 Mar;161(3):473-9 [14992973.001]
  • [Cites] Schizophr Bull. 1987;13(2):261-76 [3616518.001]
  • [Cites] Schizophr Bull. 1988;14(4):633-43 [3064287.001]
  • [Cites] Int J Rehabil Res. 1988;11(3):213-24 [2978514.001]
  • [Cites] Arch Gen Psychiatry. 1993 May;50(5):369-76 [8098203.001]
  • [Cites] Am J Psychiatry. 1994 Oct;151(10):1409-16 [8092334.001]
  • [Cites] Eur Child Adolesc Psychiatry. 1997 Dec;6(4):212-8 [9443000.001]
  • [Cites] J Nerv Ment Dis. 1998 Jun;186(6):357-63 [9653420.001]
  • [Cites] Am J Psychiatry. 2005 Mar;162(3):441-9 [15741458.001]
  • [Cites] Schizophr Bull. 2005 Jul;31(3):723-34 [16020553.001]
  • [Cites] Am J Psychiatry. 2000 May;157(5):808-15 [10784476.001]
  • (PMID = 16894026.001).
  • [ISSN] 0586-7614
  • [Journal-full-title] Schizophrenia bulletin
  • [ISO-abbreviation] Schizophr Bull
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antipsychotic Agents
  • [Other-IDs] NLM/ PMC2526146
  •  go-up   go-down


98. Cervantes-Castaneda RA, Bhat P, Fortuna E, Acevedo S, Foster CS: Induction of durable remission in ocular inflammatory diseases. Eur J Ophthalmol; 2009 Jan-Feb;19(1):118-23
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction of durable remission in ocular inflammatory diseases.
  • PURPOSE: To describe a paradigm of care for patients with ocular inflammatory diseases aimed at induction of durable remission.
  • Durable remission was defined as control of inflammation in the absence of systemic IMT for at least 1 year.
  • Thirty percent of the patients required at least 2 years of therapy with systemic IMT to obtain durable remission, while 44% required 2 to 5 years of therapy to achieve the same.
  • Twenty percent continued to stay in remission, off immunomodulatory drugs, between 2 and 5 years and 18% were in remission for more than 5 years after therapy discontinuation.
  • Durable drug-free remission is an achievable goal, and should be pursued by ocular inflammatory disease specialists.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19123158.001).
  • [ISSN] 1120-6721
  • [Journal-full-title] European journal of ophthalmology
  • [ISO-abbreviation] Eur J Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Immunologic Factors; 0 / Immunosuppressive Agents
  •  go-up   go-down


99. Gipson DS, Chin H, Presler TP, Jennette C, Ferris ME, Massengill S, Gibson K, Thomas DB: Differential risk of remission and ESRD in childhood FSGS. Pediatr Nephrol; 2006 Mar;21(3):344-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential risk of remission and ESRD in childhood FSGS.
  • In order to assess the risk of progression of children with primary FSGS and the impact of proteinuria remission status on disease progression, we undertook this study to describe a cohort of 60 children and adolescents from the Glomerular Disease Collaborative Network.
  • Complete remission was achieved in 20%, partial remission in 33%, and 47% have not achieved remission during follow-up with all prescribed therapy.
  • Only ACE-I/ARB therapy was predictive of proteinuria remission in multivariate analysis (hazard ratio [HR] 3.35; 95% confidence interval [CI] 1.42-7.92).
  • Renal survival was much improved in patients with complete or partial remission compared with no remission in univariate analysis.
  • In multivariate analysis comparing no remission status, complete remission was associated with a 90% decreased risk of ESRD (HR 0.10, 95% CI 0.01-0.79, p =0.03).
  • In summary, proteinuria remission status is a valid predictor of long-term renal survival in children with FSGS.
  • [MeSH-minor] Adolescent. Angiotensin Receptor Antagonists. Angiotensin-Converting Enzyme Inhibitors / therapeutic use. Child. Cohort Studies. Disease Progression. Glomerular Filtration Rate. Humans. Nephrotic Syndrome / etiology. Prognosis. Proteinuria / etiology. Remission Induction. Risk Factors

  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Soc Nephrol. 2004 Mar;15(3):722-32 [14978175.001]
  • [Cites] J Pediatr. 1981 Apr;98(4):561-4 [7205481.001]
  • [Cites] J Am Soc Nephrol. 2005 Mar;16 Suppl 1:S58-63 [15938036.001]
  • [Cites] J Am Soc Nephrol. 1996 Jan;7(1):56-63 [8808110.001]
  • [Cites] J Am Soc Nephrol. 2002 Dec;13(12):3016-23 [12444222.001]
  • [Cites] J Pediatr. 1984 Jun;104(6):849-54 [6726515.001]
  • [Cites] J Clin Lab Anal. 2005;19(4):160-6 [16025477.001]
  • [Cites] Clin Nephrol. 1978 Dec;10(6):213-8 [365407.001]
  • [Cites] Mayo Clin Proc. 1983 Sep;58(9):568-77 [6887974.001]
  • [Cites] Pediatrics. 1976 Aug;58(2):259-63 [951142.001]
  • [Cites] Lancet. 2003 Aug 23;362(9384):629-39 [12944064.001]
  • [Cites] Physiol Genomics. 2005 Apr 14;21(2):212-21 [15687485.001]
  • [Cites] J Pediatr. 1985 Mar;106(3):522-6 [3973793.001]
  • [Cites] Am J Kidney Dis. 2005 Feb;45(2):309-15 [15685509.001]
  • [Cites] Am J Kidney Dis. 2004 Jan;43(1):10-8 [14712422.001]
  • [Cites] Pediatr Nephrol. 2004 Jan;19(1):45-50 [14648339.001]
  • [Cites] J Am Soc Nephrol. 2004 Aug;15(8):2169-77 [15284302.001]
  • [Cites] J Nephrol. 2004 Sep-Oct;17(5):666-72 [15593033.001]
  • [Cites] Am J Kidney Dis. 1998 Jul;32(1):72-9 [9669427.001]
  • [Cites] Nephron. 1976;16(1):31-41 [1244564.001]
  • [Cites] Nephrol Dial Transplant. 2000 Sep;15(9):1348-56 [10978390.001]
  • [Cites] J Am Soc Nephrol. 2005 May;16(5):1188-94 [15800117.001]
  • [Cites] J Am Soc Nephrol. 2001 Dec;12(12):2832-7 [11729254.001]
  • [Cites] J Am Soc Nephrol. 2005 Apr;16(4):1061-8 [15716334.001]
  • [Cites] Nephron. 1978;21(2):75-85 [673092.001]
  • [Cites] J Am Soc Nephrol. 2003 Feb;14(2):448-53 [12538746.001]
  • [Cites] Am J Kidney Dis. 2004 Feb;43(2):368-82 [14750104.001]
  • (PMID = 16395603.001).
  • [ISSN] 0931-041X
  • [Journal-full-title] Pediatric nephrology (Berlin, Germany)
  • [ISO-abbreviation] Pediatr. Nephrol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Angiotensin Receptor Antagonists; 0 / Angiotensin-Converting Enzyme Inhibitors
  •  go-up   go-down


100. Moos RH, Moos BS: Paths of entry into alcoholics anonymous: consequences for participation and remission. Alcohol Clin Exp Res; 2005 Oct;29(10):1858-68
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paths of entry into alcoholics anonymous: consequences for participation and remission.
  • They also described their reasons for entering AA and/or treatment and the perceived benefits of these sources of help RESULTS: Compared with individuals who initially participated only in treatment but later entered AA, those who entered treatment and AA together participated in AA longer and more frequently and were more likely to achieve remission.
  • Among individuals who initially participated only in AA, those who later entered treatment had poorer remission outcomes than those who did not enter treatment.
  • Longer duration of participation in AA was associated with a higher likelihood of remission at all four follow-ups; individuals who dropped out of AA were more likely to relapse or remain nonremitted.
  • CONCLUSIONS: Compared with individuals who participated only in professional treatment in the first year after they initiated help-seeking, individuals who participated in both treatment and AA were more likely to achieve remission.

  • MedlinePlus Health Information. consumer health - Alcoholism and Alcohol Abuse.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16269916.001).
  • [ISSN] 0145-6008
  • [Journal-full-title] Alcoholism, clinical and experimental research
  • [ISO-abbreviation] Alcohol. Clin. Exp. Res.
  • [Language] eng
  • [Grant] United States / NIAAA NIH HHS / AA / AA12718
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down






Advertisement